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Introduction: Despite improvements in the understanding of infant death over 
recent years, many infants die each year in whom no cause of death is 
identified. There is evidence to suggest that a proportion of these unexplained 
deaths are the consequence of infection, either by a classical mechanism or as 
a consequence of the action of bacterial toxins. Post mortem tests for bacteria 
are robust, but there is a lack of effective post mortem tests for inflammatory 
markers which might assist in the interpretation of bacteriological results, and 
for identification of bacterial toxins. 
Methods: Proteomic techniques including biomarker discovery techniques 
using liquid chromatography mass spectrometry, and targeted techniques using 
multiple reaction monitoring tandem mass spectrometry, were used to identify 
potential biomarkers for infection and identify bacterial organisms and toxins, 
with a view to creating clinically-useful tests. 
Results: First, a rapid test for three biomarkers was developed which allows 
identification of infection and sepsis with high sensitivity and specificity in post 
mortem liver samples; this may be rapidly translated for clinical use.  Second, a 
highly specific and sensitive test for Staphylococcus aureus and seven 
Staphylococcal exotoxins was developed which may be used to study the 
significance of Staphylococcal toxins in infant deaths. Furthermore this 
technique may adapted to identify other organisms; allowing potential use as a 
rapid diagnostic test in clinical practice in the living. Thirdly, the tests developed 
have identified inflammatory markers which are decreased in infants dying of 
infection; raising the possibility that acquired immune paresis may contribute to 
these deaths. This finding contributes to the understanding of mechanisms of 
fatal infection in infants, and in their prevention and management. Finally, a 
number of mitochondrial proteins have found to be raised in SIDS cases, which 
may provide additional insight into the mechanism of death in some of these 
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The aim of this work is to utilise proteomic techniques to allow the development 
of: 
 
 A specific and sensitive direct test for Staphylococcus aureus and its 
major exotoxins in order to allow: 
o Proof of principle that such a test can be created 
o Use of the test to investigate further the role of bacterial toxins in 
SIDS 
o Use of the method for the development of clinical tests to allow 
rapid identification of bacteria and bacterial toxins in the living 
 
 
 A sensitive and specific multiplex test for inflammatory markers in order 
to allow: 
o Accurate identification of infection and sepsis as causes of death 
in infants in clinical post mortem practice 
o Determination of what proportion of unexplained infant deaths, if 
any, is attributable to infective causes 
 
 
 Reliable tests for biomarkers which may be used to enhance the 
understanding of the mechanisms underlying unexplained infant deaths 

















Over the last 50 years, thanks to education and research efforts, the number of 
infant deaths in the United Kingdom has dropped dramatically. In 2014 there 
were 2,517 deaths in children under one year of age in England and Wales, 
compared with 6,037 similar deaths in 1984 [ONS 2016]. While this 
improvement is clearly to be welcomed, any child death is a tragedy both for 
society and for the parents. The distress caused to parents is often 
compounded by the fact that in many cases the cause of death in these infants 
cannot be identified (212 cases in 2014 [ONS 2016a]). 
Guidance from organisations such as the Royal College of Pathologists 
[RCPath, 2005] and the Royal College of Paediatrics and Child Health [RCPath 
and RCPCH 2016], has helped to ensure a minimum standard to the conduct of 
post mortem examinations in cases of infant death occurring in the United 
Kingdom. This means that wherever an infant dies in the UK, the conduct of 
their autopsy should, in general terms, follow the same procedure. However, 
despite such guidance, there is still a significant variation in the detail of how 
these autopsies are conducted and what further tests are carried out. 
Furthermore, and more significantly, there is marked variation in the UK and 
worldwide with regard to interpreting the results of such investigations [Pryce et 
al 2011]. Due to the poor understanding of the aetiology of these deaths and a 
lack of tests to assist in interpretation, these tests are often interpreted by the 
pathologist conducting the examination on the basis of a combination of 
educated guesswork, precedent and instinct.  
The practical result of this is that the geographical location of the autopsy and 
the person performing it can make a significant difference to the outcome of the 
autopsy and the information given to parents. For example, if an infant were to 
die and only a single microscopic focus of bronchopneumonia were found at 
post mortem examination, depending on where in the UK the examination were 
performed and who performed it, the parents may be told either that the cause 
of death is infection, or that the cause of death remains unexplained.  
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This situation is confusing and distressing for parents, and can potentially skew 
infant death statistics such that some areas appear to have less favourable 
unexplained infant death rates than others. This may in turn have an effect on 
Public Health efforts to tackle the causes of infant death. Furthermore, this 
variability adversely affects research efforts as even if definitions of infant death 
which include post mortem findings as a factor are agreed between 
jurisdictions, the group of cases may differ due to post mortem practice 
variation. 
The reason for this variation is not usually poor practice, but rather a lack of 
robust investigations to aid in the understanding of the mechanisms underlying 
infant deaths and to assist in the interpretation of post mortem findings. Indeed, 
that part of the second edition of the Kennedy Report dedicated to the post 
mortem examination is essentially unchanged from the first edition published 
over a decade ago [RCPath and RCPCH 2004, RCPath and RCPCH 2016]. 
This is because there has been very little practical change in the investigation of 
these deaths during that period. The overall aim of the research conducted as 
part of this thesis is to create robust clinical tests which can be affordably 
applied in practice nationally to improve the interpretation and understanding of 
the mechanism underlying infant deaths and post mortem findings.  
 
1.2  Definitions 
 
In any study, accurate definitions are essential for the generation of robust and 
reproducible results. This is particularly important in the case of infant deaths, 
because the relative rarity of the cases means that effective research mandates 
the combination of cases from several centres, sometimes over National or 
International borders. Unfortunately, there is a lack of consensus with regard to 
the definitions used in infant deaths. Furthermore there is also a marked 
variation both temporally and geographically with regard to the application of 
terms [Beckwith 1970, Willinger, James and Catz 1991, Limerick and Bacon 




For the purposes of this thesis, terms and abbreviations used will be defined as 
detailed in Figure 1.1. This is generally in line with the use of these terms in the 
United Kingdom and Europe, but may be significantly different from those used 
in other jurisdictions.  




SUDI The death of an infant between the 
ages of 7 days and one year, which is 




- SUDI cases in which a cause of death 
is identified following a thorough 
review of the circumstances of death 
and a post mortem examination 
Sudden Infant 
Death Syndrome 
SIDS SUDI cases in which no cause of 
death is identified following a thorough 
review of the circumstances of death 
and a post mortem examination 
Figure 1.1 Definitions of infant death adopted in this thesis 
 
1.3  Explained Sudden Unexpected Death in Infancy 
 
Using currently available routine tests, less than half of sudden unexpected 
deaths in infancy are explained following post mortem examination and full 
review of the circumstances of death. For example, in a study of infant deaths in 
London between 2005 and 2010 using Metropolitan Police data, 57% of 477 
sudden unexpected infant deaths remained unexplained [Bamber et al 2016]. In 
a study of 546 post mortems carried out in cases of sudden unexpected infant 
death in one specialist centre, 63% remained unexplained [Weber et al 2008A]. 
Where the cause of death is explained, the majority of deaths are the result of 
infection with smaller numbers due to congenital abnormalities, cardiovascular 
disease, respiratory disease and other causes. In a study of paediatric post 
mortem examinations conducted in cases of sudden and unexpected infant 
death in one specialist centre, 58% of explained deaths were due to infection 
[Weber et al 2008B]. 
Evidence gained from analysis of post mortem data in explained infant deaths 
can be of great use in improving the understanding and investigation of some 
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specific causes or circumstances of death, for example those dying of 
myocardial disease [Bamber et al 2013], drowning [Bamber et al 2014a], and 
aspiration of foreign bodies [Bamber et al 2014b].  
 
1.4 Unexplained SUDI (SIDS) 
 
Using predominantly epidemiological studies, a number of risk factors for SIDS 
have been identified and are described in Figure 1.2.  
There are a number of factors which are considered controversial with regard to 
their influence over SIDS risk. First, deprivation and a “chaotic family 
environment” have been linked with an increased rate of SIDS. In a study of 477 
deaths in infants aged less than two years in London between 2005 and 2010, 
there was a significant association between unexplained death rate and 
deprivation score (Figure 1.3). Interpretation of such data is difficult; there are 
numerous confounding factors such as smoking rates and practical ability to 
follow safe sleep guidance [Bamber et al 2016].  It is therefore important that 
social class or level of deprivation alone is not used to victimize parents [Emery 
and Waite 2000]. Rather, the connection between deprivation and SUDI is 
evidence that public health measures should be targeted towards deprived 
groups, for example by the provision of “baby boxes” to improve sleep 
environment. 
Second, swaddling is a somewhat controversial area and the practice appears 
to be increasing in popularity. Published data would tend to suggest that the 
reported increased risk of infant death in swaddling relates to the interaction 
between swaddling and other risk factors, i.e. infants who are swaddled and 
placed prone are at greater risk than infants who are swaddled and placed 
supine [Pease et al 2016]. 
Finally, while the evidence with respect to SIDS risk is relatively clear cut, 
vaccination is still an area of some uncertainty amongst parents [Moon et al 
2016]. Unfortunately, the issue of vaccination and SIDS has become caught up 
in the (unfounded) concerns regarding vaccinations and autism. It is not 
uncommon for infants to die in the days after their routine childhood 
vaccinations, but this is likely to be coincidence of the childhood vaccination 
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schedule and the peak age for SIDS. Robust studies have continued to show 
that there is no increased risk of SIDS following vaccination [Miller et al 2015, 
Moro et al 2015a, Moro et al 2015b]. There is some evidence that vaccination 
may have a protective effect [Mitchell, Stewart and Clements 1995, Jonville-
Bera et al 2001, Fleming et al 2001, Vennemann et al 2007], but this is less 
clear cut and it has been theorized that this apparent protective effect may be 
caused by a bias towards vaccinating healthy children [Virtanen et al 2000]. 
 
Modifiable Risk Factors 
Prone sleeping [De Jonge et al 1989] 
Bed-sharing in the presence of hazardous circumstances (alcohol use, 
parental smoking, on a sofa, with premature infants) [Blair et al 2014, Blair 
et al 1999, Scheers, Rutherford and Kemp 2003, Scragg, Mitchell and 
Taylor 1993] 
Unsuitable sleep environment e.g. car safety seats [Bamber et al 2014c] 
Overheating [Burke and Hanani 2012, Rubens and Sarnat 2013] 
Use of excessive soft coverings [Kemp et al 1993, Ponsonby et al 1998] 
Parental smoking, including during pregnancy [Fleming et al 2000] 
Re-use of mattresses 
Non-modifiable Risk Factors 
Age [Bamber et al 2016] 
Male sex [Bamber et al 2016] 
Winter months [Bamber et al 2016] 
Prematurity and low birth weight [Blair et al 2014] 
Protective Factors 
Pacifier use [Alm et al 2016, Hauck, Hauck and Siadaty 2005, Franco et al 
2000] 
Breastfeeding [Alm et al 2016] 
Unclear or controversial factors (see text) 
Deprivation and chaotic family environment 
Vaccination 
Swaddling 







Figure 1.3 Deaths amongst 477 individuals aged less than two years dying in 
the Metropolitan Police area between 2005 and 2010 arranged by deprivation 
level (Indices of Multiple Deprivation Score Rank for Lower Layer Super Output 
Areas (LSOAs)) [Bamber et al 2016] 
 
1.5 Aetiology of SIDS 
 
Despite the identification of risk factors using population-based studies, the 
introduction of guidance and interventions to target them, and the resulting 
improvements in infant death rates, the aetiology of SIDS remains poorly 
understood. Over past decades, there have been numerous theories that have 
attempted to explain the phenomenon of unexplained infant death [Goldwater 
2017], including brainstem control of cardio-respiratory function, respiratory 
obstruction (inflicted and accidental), cardiac channelopathies, infection, 
anaphylaxis, thermal stress, diaphragmatic failure, carbon dioxide re-breathing, 
inborn errors of metabolism, toxic gases from mattresses and abuse.  
Some of these theories, such as the theory that toxic gases released from 
mattresses cause SIDS, have been comprehensively disproven [Warnock et al 
1995, Jenkins et al 2000]. However, many theories have accumulated a body of 
literature which provides support. In many cases, even where an individual 
theory lacks sufficient evidence to conclude that it is ‘the cause’ of SIDS, it may 
be possible that a given mechanism or group of mechanisms may account for a 
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proportion of SIDS cases when linked together. The best developed theory 
regarding multifactorial SIDS causation is the “triple risk hypothesis”, which 
suggests that SIDS occurs as a consequence of an external trigger, at a 
vulnerable stage of development, in a susceptible infant [Guntheroth and Spiers 
2002]. 
Despite the relatively widespread recognition of the triple risk hypothesis it is 
relatively common, even in the infant death literature, for experts to discuss 
SIDS cases in terms which suggest that they are a consequence of a single 
mechanism. For example, even in the most recent literature experts have 
suggested that a single hypothesis is the ‘key’ to SIDS and that only this factor 
satisfactorily links the other known risk factors [Goldwater 2017, Siren 2017]. 
Furthermore these authors also suggest that other avenues of investigation in 
SIDS be abandoned in favour of their favoured mechanism. Siren suggests that 
as genetic/congenital factors are not part of their theory they are not likely to be 
useful avenues of research in SIDS [Siren 2017], whilst Goldwater criticizes the 
approach of identifying a specific possible cause of SIDS and investigating it 
further [Goldwater 2017]. 
There could be considered a flaw in this view of SIDS investigation and 
causation as it relies on a premise that SIDS is a ‘disease’, i.e. all, or the 
majority of, deaths categorized as SIDS are the consequence of a single 
underlying cause or mechanism. As can be established from a review of the 
SIDS definition given above, SIDS is in fact an ‘umbrella’ term for all deaths 
which are otherwise unexplained occurring in similar general circumstances in 
children of a similar age. While some of these cases may share an underlying 
mechanism, it seems inevitable that previously unidentified causes of death will 
be discovered which remove deaths from this group. A good example of this is 
Medium Chain Acyl-Co-A Dehydrogenase Deficiency (MCADD); a metabolic 
disease which was defined relatively recently. Deaths due to this disease in the 
past would have been given a diagnosis of SIDS. However, since the inclusion 
of MCADD in newborn screening tests, it has become extremely rare to die of 
the condition, and even where deaths do occur the disease will be picked up on 
routine post mortem investigations. Over time, it seems likely that the group of 
SIDS cases will be gradually reduced in size as improved post mortem tests 
and the recognition of new disease entities moves increasing numbers of cases 
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into the ‘explained’ category. It may be that a small subgroup emerges with a 
common mechanism, but until that time it makes most sense to scientifically 
explore all possible causes. 
 
1.6 Infection and infant death 
 
While the above comments regarding aetiology of SIDS should be borne in 
mind, there is a significant body of evidence, both in terms of laboratory 
research and risk factor analysis, which suggests that a proportion of SIDS 
cases may be the consequence of infection.  
A number of the risk factors discussed above could be explained by an infective 
aetiology. SIDS cases are more common in the winter months, when viral 
infections are more common. There is some evidence that vaccination may 
have a protective effect in respect to SIDS [Fleming et al 2001, Muller-Nordhorn 
et al 2015]. It is common in post mortem examination in SIDS cases to find 
evidence of non-specific inflammatory changes, such as peribronchial and 
perivascular lymphoid aggregates in the lungs. A common feature in many 
SIDS cases is the history of preceding coryza or upper respiratory tract 
infection, and there is some evidence to suggest that when compared with 
controls, SIDS cases have increased inflammatory changes in the laryngeal 
epithelium and sub-epithelium [Scadding et al 2014]. In addition to these 
factors, it must be considered that infection is by far the most common cause of 
explained SUDI and post mortem tests have significant limitations; it is therefore 
likely that some cases of infection are missed and then incorrectly labelled as 
SIDS cases. 
A number of genetic variants of common pro- and anti-inflammatory cytokines 
have been reported to be increased in SIDS cases compared with controls, 
most notably Interleukin-1 (IL-1), Interleukin-1 receptor antagonist, Interleukin-6 
(IL-6), Interleukin-10 (IL-10), Interleukin-10 promoter, Tumour Necrosis Factor 
alpha (TNFα), and Vascular Endothelial Growth Factor (VEGF) [Summers et al 
2000, Opdal 2004, Dashash et al 2006, Highet, Gibson and Goldwater 2010a, 
Ferrante and Opdal 2015, Ferrante et al 2013, Moscovis et al 2006]. However in 
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other studies the reported increase in SIDS groups has failed to be reproduced 
(e.g. Interleukin-10 promoter) [Courts and Madea 2011].  
The colonization of the gut with bacteria in early infancy is thought to play a 
major role in the development of a healthy immune system. It has been reported 
that the gut microbiome in infants dying of SIDS differs significantly from that in 
control babies, and it has been theorized that this may reflect a degree of 
immune compromise. It has also been suggested that this may explain the 
increased risk of SIDS in babies who sleep prone [Highet et al 2014, Goldwater 
2015]. 
Distinct patterns of C-reactive protein (CRP) and Intercellular Adhesion 
Molecule 1 (ICAM-1) have been reported in SUDI cases depending on cause of 
death, but were not found to be raised in SIDS cases [Pryce et al 2014]. This 
raises the possibility that death in SIDS cases may be unrelated to infection, or 
possibly occurring via an alternative mechanism to classical sepsis. One 
possible alternative mechanism is the development of the so-called ‘cytokine 
storm’. This has been raised as a possibility in a small number of SIDS infants 
following the identification of extremely high levels of Interleukin-6 (IL-6) 
[Vennemann et al 2012]. 
 
1.7 Post mortem inflammatory markers in sepsis 
 
A number of inflammatory markers have been hypothesized as being of use in 
post mortem samples from deaths arising as a consequence of infection or 
sepsis. These markers have been studied in a number of bodily fluids, and in 
specific solid tissues by means of immunocytochemistry, most notably the lung.  
In a study of perinatal deaths where there was evidence of Fetal Inflammatory 
Response Syndrome (FIRS), there was an increase in various inflammatory 
markers which was linked to the underlying cause of death. Interleukin 6 was 
increased in FIRS arising in the context of congenital malformation, C-reactive 
protein was increased in FIRS arising as a consequence of ascending infection, 
and Tumour Necrosis Factor alpha was increased in cases of FIRS caused by 
perinatal anoxia [Pereira et al 2014]. 
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A number of markers have been studied in pericardial and pleural fluid; 
Procalcitonin, C-reactive protein, Soluble triggering receptor expressed on 
myeloid cells-1 (sTREM-1), soluble interleukin-2 receptor (sIL-2R), and 
Interleukin-6 (although IL-6 was not found to be a specific marker of sepsis, but 
rather of a more generalised inflammatory response) [Tsokos et al 2001, 
Palmiere and Augsberger 2014, Palmiere and Egger 2014].  
Serum and vitreous procalcitonin has also been shown to be increased in 
sepsis [Bode-Janisch et al 2013, Schrag et al 2012], although other studies 
have called into question the increase in serum procalcitonin in sepsis 
[Augsbuerger et al 2013].  
A number of markers have been suggested for identification of sepsis-related 
lung injury; Integrin alpha-4 beta-1 (VLA-4, CD49d/CD29), Intercellular 
adhesion molecule-1 (CD54), lactoferrin, vascular endothelial growth factor 
(VEGF), Pulmonary Angiotensin-converting Enzyme (ACE), and E-selectin 
[Tsokos and Fehlauer 2001, Tsokos 2003, Tsokos, Fehlauer and Puschel 2000, 
Muller et al 2008]  
Despite a number of reports highlighting their potential utility in post mortem 
practice, none of these markers are currently in routine diagnostic use in the 
United Kingdom. This may relate to the cost and complexity of setting up 
assays for individual markers in units where they would only be infrequently 
used. 
 
1.8 Bacterial toxins and SIDS 
 
The possibility that common bacterial toxins may account for SIDS cases was 
first hypothesized in 1987, when it was suggested that bacteria proliferating in 
the upper respiratory tract might produce toxins resulting in the death of the 
infant. This, it was theorized, would account for the minimal changes at autopsy, 
the common feature of preceding viral infection, and the age distribution in SIDS 
cases [Morris, Haran and Smith 1987]. 
In the decades since this hypothesis was first published, the theory has been 
further investigated by a number of methods. A number of Staphylococcal 
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toxins (Enterotoxins A, B, C, D, Toxic Shock Syndrome Toxin 1 (TSST-1), and 
Alpha-haemolysin), were identified more commonly in SIDS cases than controls 
using immunohistochemical staining and gel-based techniques [Newbould et al 
1989, Malam et al 1992]. 
In other studies, bacterial isolates from nasopharyngeal samples were used to 
create crude toxin preparations which were applied to early chick embryos. It 
was determined that infants dying of SIDS had a significantly higher probability 
of having lethally toxigenic bacteria in their nasal flora than controls 
[McKendrick et al 1992]. Further studies of lethality in chick embryos by the 
same group also demonstrated a synergistic effect when toxins from 
Staphylococcus aureus and Escherichia coli were administered to chick 
embryos together [Drucker et al 1992], and where toxins were administered with 
very low doses of nicotine [Sayers et al 1995]; this latter finding providing a 
possible explanation for the association between SIDS and smoking.  
Results of examination of antibodies to common bacterial toxins in SIDS infants 
and controls suggested that many infants are exposed to bacterial toxins and 
develop immunity. However in SIDS infants there is evidence of a lower 
Immunoglobulin A response to Staphylococcal toxins than controls [Siarakas, 
Brown, and Murrell 1999]. It has also been suggested that variation in the genes 
encoding common inflammatory cytokines may negatively impact the 
physiological response to some bacterial toxins. For example, single nucleotide 
polymorphisms in the gene encoding Interleukin-1 beta (IL1β) are hypothesized 
to contribute to an attenuated response to TSST-1, particularly in the context of 
cigarette smoking [Moscovis et al 2004]. However, a study examining the role of 
polymorphisms of T cell receptor BV3 recombination signal sequence (a 
Staphylococcal enterotoxin receptor gene) showed no significant difference 
between SIDS cases and controls [Highet, Gibson, and Goldwater 2010b]. 
A number of studies have demonstrated that toxigenic bacterial strains of 
Staphylococcus aureus and Escherichia coli are commonly isolated in infant 
deaths of all causes, with no significant difference in toxigenic strains isolated 
from infants dying of explained causes and SIDS [Highet et al 2009, Highet and 






While there is a substantial body of evidence that raises the possibility that at 
least some cases of SIDS are the consequence of infection or inflammatory 
mechanisms, there is a lack of widely available tests which could be applied in 
practice to investigate this possibility further. The body of research in this piece 
of work will comprise the use of proteomic techniques to further investigate the 









The term ‘proteome’ was first used to describe the “total protein complement 
able to be encoded by a given genome” [Wasinger et al 1995]. Proteomics can 
therefore be defined as the study of the proteome (i.e. the complete set of 
proteins expressed by an organism, tissue, or cell). It includes the study of 
changes in protein expression patterns as related to diseases and 
environmental conditions. By comparing proteomes from different disease 
states (comparative proteomics), candidate biomarkers can be identified which 
may form the basis of tests for the disease of interest. These techniques have 
dramatically altered the approach to determination of disease aetiologies and 
mechanisms in life and have the potential to do the same for investigation after 
death. Specifically, such novel tests may in future allow more accurate 
determination of the cause, mode and timing of death and may alter the overall 
strategy for investigation after death. In the perinatal and paediatric setting, 
such approaches have particular application since in this population, specific 
genetic disorders are more common, and disease processes are likely to be 
more detectable due to the relative absence of co-morbidities and 
environmental influences. Background to the specifics of the technical aspects 
of proteomics is given in Chapter 3. Here follows an introductory discussion of 
the ways in which proteomic techniques have been applied to the investigation 
of infant deaths to date. 
 
2.2 Animal post mortem data 
 
While the focus of this thesis is clearly deaths in humans, application of 
proteomics to other species has been of great use in establishing the effect of 
post-mortem changes on the proteome. Much of this data comes from studies in 
the meat industry, in which quantification of how muscle (meat) changes in the 
period from death is important for meat quality. Nevertheless, such data provide 
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useful general data regarding post-mortem proteomic applications and 
assessment of post mortem changes.  Such data is based on both two-
dimensional electrophoresis and mass spectrometry-based proteomics. 
Changes in relative values of specific muscle proteins are described during the 
post mortem interval including changes in actin fragments and myosin heavy 
chain fragments [Lametsch and Bendixen 2001, Lametsch et al 2003]. Of the 
proteins that change most during the initial PM period, these include metabolic 
enzymes, stress proteins, structural proteins, proteolytic enzymes, and 
otherwise unclassified proteins. Metabolic enzymes are predominantly 
associated with the glycolytic pathway or energy metabolism [Jia et al 2007].  
Such changes demonstrate distinct patterns of temporal expression, with 
different groups of proteins changing at different points in the post mortem 
period, with association analysis suggesting potential biomarkers for features of 
interest [Te Pas et al 2009, Bjarnadottir et al 2010]. Similar data are available 
from fish storage, also demonstrating degradation of myosin heavy chains and 
glycolytic enzymes [Terova et al 2011]. Furthermore, principal component 
analysis demonstrates the effect of mode of slaughter, with asphyxial modes 
clustering together [Addis et al 2012, Grabez et al 2015].  
 
2.3 Human post mortem data 
 
Use of both two-dimensional difference gel electrophoresis (2-D DIGE) and 
mass spectrometry have also been well reported for proteomic investigation of 
human post mortem samples [Swatton et al 2004]. Analogous to the animal 
data, post mortem muscle specimens show upregulation of certain transcripts 
involved with protein biosynthesis, responses to oxidative stress, hypoxia, and 
ischemia. The data demonstrate that post mortem samples undergo an active 
transcriptional phase during the initial post mortem period [Sanoudou et al 
2004]. In other tissues, such as brain, proteomic approaches can result in 
confident identification of proteins, which has been particularly useful in the 
investigation of the mechanisms underlying neurodegenerative disorders 
[Dumont et al 2006]. The successful use of post mortem fluids such as CSF for 
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proteomic analysis demonstrates a range of proteins with significant change in 
concentration in relation to post mortem interval [Finehout et al 2006].  
Studies on post mortem muscle biopsies stored for varying periods up to 48 
hours have demonstrated that at 4°C, the proteome profile is largely unchanged 
until 24 hours, after which there is a reduction in number of proteins identified, 
corresponding to 12 hours at room temperature [Tavichakorntrakool et al 2008]. 
This is similar to work with brain tissue reporting that 12 hours appears to be 
critical time point for preservation at room temperature, whereas after 
refrigeration at 4°C, most phosphoproteins are stable for at least 72 hours [Oka 
et al 2011]. Liquid chromatography mass spectrometry has also been used to 
identify specific elements for subsequent proteomic investigation [Liu et al 
2011].  
 
2.4 Use of formalin-fixed paraffin-embedded (FFPE) material 
 
Most diagnostic pathology departments, including forensic pathology, have 
existing diagnostic archives of well characterised cases with FFPE tissue 
samples. The ability to use such retrospective resources if of great use in many 
rare diseases, and in the context of this study is vital in the investigation of 
SUDI; the relatively small number of cases in each centre per year meaning 
single centre prospective data collection might take many years. The nature of 
formalin-fixation and paraffin-embedding introduces complications which require 
adaption of the techniques used in fresh tissue; the specific difficulties are 
discussed in Chapter 3. Despite these complications FFPE material has now 
been successfully used for a number of ‘omic’ techniques. 
Use of FFPE material has now been widely described including various 
methods for extraction of DNA and RNA [Okello et al 2010]. Post mortem FFPE 
tissue samples have also been used for polymerase chain reaction 
amplification, and DNA sequencing. Some genes were stable regardless of 
fixation time whereas others reduced in yield with increasing fixation time 
[Ferruelo et al 2011]. FFPE results in partially degraded RNA; the interpretation 
of which can be optimised with specific platforms [Chow et al 2011]. 
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Formalin-fixed paraffin-embedded tissue taken at the time of post mortem 
examination has been successfully used for proteomic investigation and has 
resulted in the identification of a number of clinical biomarkers [Murray 2012]. 
This is of particular interest in rare conditions such as paediatric tumours and 
neurodegenerative disorders, where post mortem samples may be the only 
samples available for testing [Nazarian et al 2008, Drummond et al 2015] 
 
2.5 Other techniques; metabolomics and metagenomics (microbiome) 
 
Other laboratory investigations have recently started to become applied to the 
PM setting, although the complexity in their interpretation remains. For example, 
rat femoral muscles alter their metabolic profiles after death depending on the 
mode of death and post mortem interval [Hirakawa et al 2009]. Similarly, mass 
spectrometry for a range of metabolites could separate groups of animals based 
on the time since death; illustrating the potential for metabolic profiling to 
determine post mortem interval under certain conditions [Sato et al 2015].  
Evaluation of the human microbiome has allowed determination of changes in 
gut bacterial populations with increasing post mortem interval and demonstrated 
for example, that Bacteroides and Lactobacillus relative abundances decline 
with increasing post mortem interval, and could be used as quantitative 
indicators of time since death [Hauther et al 2015].  
Despite the proven utility of these techniques in post mortem tissue, such 
techniques are of limited application in formalin-fixed paraffin-embedded tissue, 
where the nature of processing means that proteins present at a low abundance 




Proteomics has been successfully applied to post mortem material including the 
analysis of formalin-fixed paraffin embedded samples. Despite the well 
documented changes in protein structure and the proteome in the post mortem 
period in both animals and humans, useful data in disease groups has been 
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obtained. This has allowed the detection of biomarkers for rare tumours and 
neurodegenerative diseases. The use of formalin-fixed paraffin-embedded 
tissue for proteomics allows the inclusion of large number of cases in rare 
conditions, including infant deaths, where prospective tissue collection would 
take many years. However, the use of this tissue requires refinement of the 
















Chapter 3 - Methods and Method Development 





Any study of causes of death necessitates the collection of large quantities of 
post mortem material for analysis. Infant deaths are relatively rare occurrences 
and arise as a consequence of a number of different aetiologies. Prospective 
collection of tissue samples from a sufficiently large number of cases in defined 
disease groups would therefore take many years and necessitate the 
involvement of a large number of centres. Since there is marked variation in 
autopsy practice between centres, there would be serious concerns regarding 
reliable comparison of cases investigated in different centres.   
These problems may be avoided by the use of archived tissue taken over the 
course of many years at a single centre. Histopathology departments have large 
stores of such material stored as ‘blocks’ of tissue embedded in paraffin wax 
(Figure 3.1).  
 




The use of such material circumvents the difficulties of sample collection and 
inter-department variation in practice [Ralton and Murray 2011]. The process of 
production of such blocks from post mortem material is as follows. 
When a post-mortem specimen is received into the laboratory it is first “fixed” in 
a solution of 10% neutral buffered formalin (approximately 3.7% formaldehyde 
in phosphate buffered saline), for a variable period of time which depends on 
local turnaround time requirements, laboratory pressures, and tissue type. This 
preserves the tissue by means of a combination of reversible and irreversible 
protein cross linking of primary amino groups (principally the amino side chain 
of lysine) to nearby nitrogen atoms with a methylene bridge (-CH2-) (Figure 3.2) 
[Howat and Wilson 2014]. There is also evidence that cross linking can occur 
between aminomethylol groups and phenol, indole and imidazole side chains by 
a form of the Mannich reaction [Fraenkal-Conrat and Olcott 1948]. Cross links 
are formed both within individual proteins and between separate proteins; 
preventing, or significantly slowing, the process of protein breakdown. 
 
 
Figure 3.2 Chemical cross-linking of proteins by formaldehyde; the ammonium 
cation mechanism [Nadeau and Carlson 2007] 
The fixed tissue is dehydrated by serial washes in increasing concentrations of 
ethanol (usually in the form of 99% industrial methylated spirit, IMS), typically 
ranging in concentration from 70% to 99%. As ethanol is non-miscible with 
paraffin wax, a clearing agent that is miscible with both the dehydrating agent 
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and with paraffin wax is required to form a bridge between these stages of the 
process. Xylene is the usual reagent used for this purpose. 
Following clearing with xylene, the tissue is infiltrated with paraffin wax; a 
mixture of alkanes with the chemical formula CnH2n+2, where n falls within the 
range 20 ≤ n ≤ 40. Finally, the tissue is embedded in a mould of paraffin wax to 
form a ‘block’ which provides mechanical support and allows mounting on a 
microtome for sectioning. Wax blocks can be stored at room temperature and 
remain stable for very long periods. A more detailed discussion of the variations 
in tissue processing commonly used is available from numerous specialised 
texts [for example Smith and Warfield 2005].  
While the use of formalin-fixed paraffin-embedded tissue in infant death 
research has marked advantages, there are disadvantages to using this 
material for proteomic research. Paraffin wax is not compatible with the 
methods used in proteomics, and the protein is ‘fixed’, preventing its breakdown 
or digestion. For the tissue to be useful in proteomic research the paraffin wax 
must be removed; a modification of a previously adopted method was used for 
this purpose [Pryce 2012]. Furthermore, even if protein is effectively recovered 
from the tissue, there are changes in protein composition that occur with 
increasing post mortem interval which may affect the interpretation of results 
(see Chapter 2). 
 
3.1.2 Tissue selection and preparation from wax block 
 
Slides from appropriate tissues from selected cases were examined using light 
microscopy and suitable areas for sampling were marked on the slide (Figure 
3.3). Using the marked slide as a guide, a 2 millimetre core of formalin-fixed 
paraffin-embedded tissue was removed from the block using a disposable 
biopsy punch (IntergraMiltex Disposable Biopsy punch, 2.0mm with plunger, 33-
31-P/25, IntergraLifeSciences Holdings Corp; Plainsboro, NJ) (Figure 3.4). 
Each core was transferred to a labelled non-siliconised polypropylene 
microcentrifuge tube (Eppendorf) using the plunger system supplied with the 
biopsy punch. The same punch was used to collect each sample, but cleaned 




Figure 3.3 Marking of a suitable area for sampling on a glass slide 
 
 
Figure 3.4 Block sampling of a pre-marked area using a punch biopsy system 
 
3.1.3 Removal of alkanes/wax from tissue to allow proteomic analysis 
 
The cores were initially heated at 60°C for 30 minutes to melt the paraffin wax, 
before being soaked in xylene for five minutes and undergoing three xylene 
washes. Rehydration was achieved by soaking in decreasing concentrations of 
proteomic grade ethanol (100%, 95%, 90%, 80%, and 70%), each for a period 
of five minutes, before immersion of the core in distilled water. This results in an 
identifiable change in colour and consistency which can be used as a proxy 
marker for successful deparaffinisation and rehydration (Figure 3.5). The 





Figure 3.5 Tissue core before and after processing showing characteristic 
colour and size change with rehydration 
 




As discussed in Chapter 2, proteomics refers to the study of the proteome; the 
complete protein complement of a cell, tissue, or organism of interest, including 
post-translation modifications [Lawrie, Fothergill and Murray 2001, Lovric 2011]. 
In general terms, proteomic analysis can follow one of two approaches; top-
down or bottom-up, with some authors advocating a combined approach 
(“middle-down”) [Moradian et al 2014]. 
Top-down proteomics involves the separation of intact proteins into fractions by 
isoelectric focussing or size exclusion. The fractions are then digested and 
subjected to mass-spectroscopic analysis [Han et al 2006, Whitelegge 2013]. 
By contrast, bottom-up proteomics relies on inferred protein identification from 
the analysis of peptides released through a process of proteolysis of all the 
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proteins using one or more enzymes. The protein mixture is first homogenised 
and then digested ‘in solution’ without prior separation by any biochemical 
techniques. The complexity of the peptide solution is then reduced by 
separation using ultra performance liquid chromatography (UPLC), conducted 
prior to electrospray induction [McDonald and Yates 2002, Zhang et al 2013]. 
Both techniques have advantages and limitations that are outlined in Figure 3.6. 
In an effort to take advantage of the benefits of both techniques and minimise 
the limitations, hybrid techniques have been created and are referred to as 
“middle-down” proteomics. Such techniques usually involve different enzymes 
than those used in bottom-up techniques [Wu et al 2012].  
 
Top-down proteomics Bottom-up proteomics 
Advantages  
The ability to simplify the proteome 
prior to mass spectral analysis by 
dividing the protein into groups (e.g. 
by size) 
No losses and less experimental 
variability when compared with “top-
down” techniques; this is better for 
quantitative and comparative 
analyses  
Much greater proteome coverage 
can be attained compared with 
“bottom-up” techniques 
Very quick and simple to perform 
Disadvantages  
Many steps; this can lead to protein 
losses and greater variability which 
can affect comparative analyses  
Requires complex liquid 
chromatography/chromatographic 
separation 
Very time consuming Technically challenging 
 Does not give as many protein 
identifications as “top-down” 
techniques 
Figure 3.6 Advantages and limitations of top-down and bottom-up proteomic 
techniques 
 
While documentation of the protein complement in healthy tissues and disease 
states can greatly advance the understanding of physiological and pathological 
cellular mechanisms, the real power of these techniques is in the field of 
comparative proteomics. In this technique two or more tissues of interest are 
subjected to analysis (e.g. disease and healthy control). The protein 
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complements of both tissues are then compared and significant differences 
between samples can be investigated further as potential biomarkers for the 
disease or condition of interest. 
Comparative proteomics can be performed using top-down techniques by 
means of differential labelling and separation of the whole proteins from the 
tissues of interest using gel electrophoresis (e.g. 2-D fluorescence difference 
gel electrophoresis (DIGE) [May et al 2012]). This is followed by selection and 
digestion of differentially expressed peptides, which are then submitted to 
sequencing by liquid chromatography mass spectrometry.  Alternatively, the 
different tissues may be investigated using ‘bottom-up’ proteomics, by 
individually submitting both samples to digestion and liquid chromatography 
mass spectrometry, and performing a statistical comparison of the calculated 
protein complement of both samples during the data analysis stage. 
For the purposes of this study, a ‘bottom-up’ strategy was used due to its high 
throughput, ability to easily compare more than two tissues, and less labour 
intensive experimental methods than gel-based techniques. In addition, given 
that the crosslinking induced by formalin fixation is unlikely to have been 
reversed, it is likely that the quality of protein separation using gel-based 
techniques would be poor. Finally, there is an advantage in the ability to create 
a validatory targeted proteome with greater ease due to compatibility within the 
laboratory in which this work was being conducted.  
In general terms the ‘bottom-up’ approach involves homogenising the tissue, 
quantitation of the protein using a protein assay, protein precipitation, reduction, 
enzyme digestion, fractionation, liquid chromatography, mass spectrometry, and 
data analysis. In this instance, a modification of previously published methods 
was used [Bennett et al 2010, Pryce 2012]. These steps are described below 
with an explanation of their purpose in the sample preparation process, and any 
method development which was required to facilitate the use of formalin-fixed 









The tissue was removed from the wax block and prepared as described 
previously (Sections 3.1.2 and 3.1.3). The rehydrated tissue cores were 
immersed in 500µL of buffer (50mM ammonium bicarbonate containing 2% 
ASB-14, pH 8.2). Ammonium bicarbonate is a useful buffer as it entirely 
decomposes to volatile compounds on lyophilisation, which allows rapid 
recovery of ‘salt free’ protein by freeze drying. ASB 14 (3-[N,N-Dimethyl(3-
myristoylaminopropyl)ammonio]propanesulfonate) is an amphiphillic zwitterionic 
detergent which allows the release of proteins from biomembranes, and 
facilitates the resolubilisation of proteins precipitated during the fixing process, 
thus making them soluble and accessible to proteases.  
The cores were then homogenised for 30 seconds divided into three ten-second 
bursts with a ten-second pause between each (where the solution was cooled 
on ice), using an electronic homogeniser (Omni Tissue Homogeniser with Hard 
Tissue Tip, TH115-PCRH, Omni International Inc; Kennesaw, Georgia) (Figure 
3.7). The use of the electronic homogeniser results in a significant time saving, 
and greater efficiency when compared to hand homogenisation, which typically 
requires more than fifteen minutes per sample. 
The homogenates were then sonicated for six cycles of ten seconds, with ten 
second pauses between each, with care taken to avoid overheating and protein 
oxidation by cooling in an ice bath. The samples were then centrifuged at 10000 
x g for five minutes to remove any residual cellular debris. 
 
3.2.3 Protein assay  
 
For accurate comparison of two or more samples, quantitation of the protein 
content of each sample is necessary in order that equal masses of protein are 
submitted to analysis. Quantitation is achieved using a protein assay; 
techniques based on a protein-dependant colour change in a solution which 




Figure 3.7 Homogenisation of tissue sample in buffer using an electronic 
homogeniser 
 
A number of protein assay techniques have been used in the literature in 
formalin-fixed paraffin-embedded samples including the Smith/Pierce 
(bicinchoninic acid/copper sulphate) [Smith et al 1985], Bradford [Bradford 
1976], and modified Lowry assays [Lowry et al 1951]. The Smith assay has 
been used most frequently in this sample type and, as several of the other 
assays cannot be used in the presence of detergents, this assay was selected 
for use in this study. 
In the Smith assay, solutions of bicinchoninic acid and copper sulphate are 
added to a small aliquot of the protein homogenate. The peptide bonds in the 
protein facilitate the reduction of Cu2+ ions in Copper (II) sulphate to Cu+ ions 
(the Biuret reaction [Gornall, Bardawill and David 1949]). The reduction of Cu2+ 
ions is proportional to the amount of protein in solution. Two molecules of 
bicinchoninic acid chelate with each Cu+ ion; forming a coloured product which 
absorbs light strongly at a wavelength of 562nm. The absorption spectra of the 
homogenate and of protein samples of known concentrations (e.g. serial 
44 
 
dilutions of bovine serum albumin), may then be compared to allow quantitation 
of the protein content.  
When this assay was utilised in this study, it was noted that there was an 
extremely wide variation in results when analysis of a single sample was 
repeated under identical conditions. It was hypothesised that some element of 
the process of formalin-fixation and/or paraffin embedding was interfering with 
the assay. It has been established that there are differences in protein structure 
and modification between fresh frozen and formalin-fixed paraffin-embedded 
samples [Sprung et al 2009]. To investigate this further, two sets of small 
samples of increasing volume were taken from fresh frozen and formalin-fixed 
paraffin-embedded liver from the same case. The samples were subjected to 
the Smith assay (as described above and in the appendix), the Pierce assay 
(Pierce 660nm Protein Assay Kit, Thermo Scientific, 22662SPLC), and the 
Lowry assay (Modified Lowry Protein Assay Kit, Thermo Scientific, 23240). A 
commercially available ionic detergent compatibility reagent (Thermo Scientific, 
22663) was used according to manufacturers recommended methodology. 
Despite the addition of the ionic detergent compatibility reagent, both the 
Modified Lowry and the Pierce assays resulted in a coagulated sample which 
could not be subjected to colorimetry. 
The results of the Smith assay are given in Figure 3.8. The standard curve had 
an r2 value of 0.982; demonstrating no evidence of error in the performance of 
the assay. The r2 values for the study groups clearly demonstrate that there is 
poor correlation between the weight of tissue processed and the concentration 
of the protein solution as measured by the assay. The reason for this is unclear 
given that the fresh-frozen tissue has a similarly poor performance to the 
formalin-fixed paraffin-embedded tissue, but it is possible that the innate 
properties of the histological processing have contributed. Given the concerns 
regarding use of the assay, comparison was conducted using wet weight rather 




Figure 3.8 Graphs of tissue weight (g) vs. protein concentration (mg/ml) 
demonstrating poor correlation. Fresh frozen tissue (A, B) and formalin-fixed 
paraffin-embedded tissue (C, D) 
 
3.2.4 Protein precipitation 
 
Prior to digestion for mass spectral analysis, a process of precipitation is 
necessary to concentrate the protein present and to remove interfering 
substances used in the resolubilisation process e.g. salts. Solubility of proteins 
is dependent on the proportion of hydrophilic and hydrophobic amino acid 
residues at the surface of the protein and interactions with the solvent. 
Electrolytic solutions form a solvation layer (hydration layer) around the 
hydrophilic surface residues of a protein. This establishes a concentration 
gradient around the protein, with the highest concentration at the protein 
surface. This network has a dampening effect on the attractive forces between 
proteins, which prevents them from precipitating. 
During precipitation a miscible solvent is added to the protein solution to disrupt 
the hydration layer around the protein. This results in gradual displacement of 
water from the protein surface; the water molecules then forming small 
hydration layers around the organic solvent molecules. Since the hydration 
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layers around the protein are significantly reduced, electrostatic and dipole 
forces between the protein molecules allow aggregation of the protein. 
A number of solvents have been used for protein precipitation including 
acetone/trichloroacetic acid [Mechin, Damerval and Zivy 2007], sodium dodecyl 
sulphate/trichloroacetic acid [Schaffner and Weissmann 1973, Retz and Steele 
1977] and chloroform-methanol [Wessel and Flugge 1984]. Because of its 
reliable performance as a general extraction solvent, with particular efficacy in 
removing lipids, and hence residual wax, the chloroform-methanol method was 
used in this study (Wessel and Flugge 1984). This method involves the addition 
of a mixture of chloroform and methanol, and then allows effective precipitation 
of the protein without the formation of a bilayer. 
For this study, chloroform-methanol was prepared in a ratio of three parts 
methanol to one part chloroform, and added to the samples at a ratio of three 
parts chloroform-methanol to one part sample. The mixture was mixed 
thoroughly for 30 minutes and kept overnight at -20°C before centrifugation at 
13,000 x g for two minutes. The supernatant was aspirated and discarded, and 
the protein pellet was freeze-dried. 
 
3.2.5 Reduction and enzyme digestion 
 
Prior to mass spectrometry, the protein pellets are resuspended and the protein 
digested into peptides. Digestion is facilitated by the addition of detergents 
(urea and ASB-14), which denature the tertiary structure of the proteins and 
increase their solubility and increases the accessibility of the proteins to the 
enzyme.  The accessibility of proteins and efficiency of digestion is also 
facilitated by reduction of disulphide bridges by 1,4-dithioerythritol, and 
carbamidomethylation of free thiol groups by 2-iodoacetamide. 
The protein pellets were reconstituted in 20 µL of 100mM Tris, pH 7.8, 
containing 6M urea and 1% ASB-14. The solution was vortexed well and left 
shaking at room temperature for one hour. 1.5 µL of 100mM Tris containing 
0.195M 1,4-dithioerythritol, pH 7.8, was added and the sample vortexed again 
and left at room temperature for a further hour. 6 µL of 100mM Tris containing 
0.195M 2-iodoacetamide, pH 7.8, was then added, before being vortexed again 
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and left at room temperature for thirty minutes. Enough distilled water was 
added to make a total volume of 200 µL. 
Digestion was achieved with endoproteinase Lys-C and trypsin. 2µg of 
endoproteinase Lys-C was added to the sample and incubated for two hours at 
37°C. Trypsin was provided in the form of lyophilised 1mg aliquots (Sigma-
Aldrich Company Ltd, Gillingham; UK), which were each reconstituted with 11µl 
of 40mM ammonium bicarbonate, with 10% acetonitrile. The resuspended 
trypsin was added to the sample and vortexed, before incubation for at least 16 





In order to increase peptide identification, each sample can be split 
(fractionated) into a number of smaller samples (fractions) based on a peptide 
characteristic of interest, such as hydrophobicity, using a form of reverse phase 
chromatography. This is achieved using a column packed with a non-polar, 
hydrophobic stationary phase, such as silica modified with silyl ethers 
containing non-polar alkyl groups such as C4, C8, or C18. The peptides in the 
solution adsorb to the stationary phase in the column; those with high net 
hydrophobicity adsorbing most effectively. Peptides are then eluted from the 
column with increasingly hydrophobic solutions; allowing the lowest 
hydrophobicity peptides to be washed into solution at each stage of elution. 
For this study, high pH C18 fractionation was conducted using an Isolute 50mg 
C18 column (220-0005A). The column was primed with 1ml of 50% acetonitrile 
containing 0.1% ammonia. Equilibration of the column was achieved by the 
addition of 2ml of a solution of 0.1% ammonia. 
The digested peptide sample was prepared by addition of 400µl of a solution of 
0.2% ammonia to 100µl of the protein digest, before being vortexed and 
centrifuged at 13,000 x g for five minutes. This was then added to the column 
and allowed to flow through under gravity, caught, re-applied to the column, and 
washed through with 500µl of 0.1% ammonia.  
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For this study the mobile (liquid) phases used were 500µl of solutions of 3%, 
5%, 8%, 10%, 15%, 25%, 35%, 50%, and 100% acetonitrile containing 0.1% 
ammonia, and 100% methanol. Each fraction was dried using a speed vac and 
reconstituted in 30µl of a solution of 3% acetonitrile containing 0.1% 
trifluoroacetic acid. A specified amount (5pmol) of marker peptide from yeast 
enolase Saccharomyces cerevisiae (ATCC 204508/S288c) was then added to 
allow quantitation. 
 
3.2.7 Liquid chromatography 
 
Ultra performance liquid chromatography (UPLC) is used for separation of the 
peptides prior to electrospray induction. This approach also allows visual 
examination of the chromatogram to assess the quality of the data being 
obtained both within and between runs. A nanoACQUITY UPLC system 
(Waters Corporation; Milford, MA) was utilised for UPLC. This consists of a 
column packed with C18-labelled silica particles (‘stationary phase’) through 
which the peptide-containing solution (‘mobile phase’) is injected. The 
interaction between the C18-labelled silica particles and the peptides results in 
adsorption of the peptides. Injection of different concentrations of organic 
washes results in a staged elution of the peptides.  An example tabulated and 
diagrammatic representation of a typical elution method is given in Figure 3.9. 
Given the use of formalin-fixed paraffin-embedded source material when 
compared to the usual fresh materials utilised in proteomics, and the need to 
maximise protein identifications, it was decided to optimise the elution process 
by varying the gradient and time period over which the elution was conducted. A 
total of 28 elution methods were designed and programmed. Each was run 
using the same digest from a core of formalin-fixed paraffin-embedded liver, 
which was processed using the above described method.  The number of 
protein identifications for each sample is given in Figure 3.10. The most 
effective method tested comprised linear elution between 3% and 55% 
acetonitrile over thirty-four minutes of the forty-five minute cycle (Figure 3.11); 
the remainder of the time being given over to elution at 99% acetonitrile to 
remove contaminants from the column prior to the next run. Elution was 
 performed over a total period of forty











Figure 3.9 Tabulated and graphical representation of a typical 45 minute liquid 
chromatography inlet method
 
The improvement resulting from this method development can be
clearly in the chromatography 
using the original and optimised methods. There is a significant increase in 
protein identifications and 
period of the method (Figures 
spectrometer being able to sequence more peptides and hence increase the 







-five minutes as a compromise between 
 Flow 
%A 
(Water) %B (ACN) 
0.3 97 3 
0.3 97 3 
0.3 60 40 
0.4 1 99 
0.4 1 99 
0.35 97 3 
0.3 97 3 
 
elution profiles shown in Figures 3.12
greater chromatographic separation 
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Figure 3.10 Protein identifications achieved with different liquid chromatography 
inlet methods in the same clinical sample 
 
The complete liquid chromatography method using the optimised inlet method 
was therefore as follows: peptides were trapped and de-salted before reverse 
phase separation using the UPLC pre-column (Symmetry C18 5µm, 5mm x 300 
µm) at flow rate of 4µl/min in 0.1% formic acid for a total time of four minutes. 
Peptides were then eluted off the pre-column and separated on the reverse 
phase analytical column (Symmetry C18, 15 cm x 75µm) using the optimised 





















Figure 3.12 Comparison of chromatography from a sample analysed using old 
(green) and optimised (red) liquid chromatography inlet methods. 
protein identifications (‘hits’) is




(Water) %B (ACN) Curve
0.3 97 3 
0.3 97 3 
0.3 50 50 
0.5 1 99 
0.5 1 99 
0.35 97 3 
0.35 97 3 
 
















Figure 3.13 Computer reconstructed ‘gel’ of the two samples shown in Figure 
3.12 demonstrating improved spread 
 
3.2.8 Mass spectrometry 
 
Following elution from the LC column, the peptides are ionised by spraying a 
continuous volume of peptide mixture through a cone through which an electric 
current is applied (electrospray). The ionised peptides are then guided through 
the vacuum of the mass spectrometer by means of an electromagnetic field 
generated by a quadrupole. In conjunction with a time of flight component, this 
allows highly detailed analysis of the mass/charge ratio of the peptides. 
Using previously defined standard laboratory protocols [Bennett et al 2010], 
peptides were analysed in positive ion mode using an ESi Q-Tof Premier mass 
spectrometer (Waters Corp, Manchester; UK). Post calibration of data files were 
corrected using the doubly charged precursor ion of [glu1]-fibrinopeptide B (m/z 
785.8426), with a sampling frequency of 30 seconds. Mass data were collected 
in a data independent and alternating low and high collision energy mode. Each 
low/high acquisition was 1.5 seconds with a 0.1 second interscan delay. A 
constant collision energy of 4 Volts was used for low collision energy data 
acquisitions. A 15-40 Volt ramp over a 1.5 second time period was used for 
high-energy acquisitions. A complete low/high collision energy acquisition was 







3.2.9 Data analysis 
 
Complex bioinformatic software is used to match peptide fragments to protein 
sequences; resulting in a statistical likelihood of a protein being present in the 
original protein sample [Washburn, Wolters and Yates 2001]. In this instance, 
data were analysed using ProteinLynx Global Server (PLGS) version 2.5 
(Waters Ltd, Elstree; UK). The amino acid sequence for yeast enolase 
Saccharomyces cerevisiae (P00924) was added manually to the human UniProt 
database. Protein identification from the low/high collision spectra for each 
sample was processed using a hierarchical approach requiring matching of at 
least three fragment ions per peptide, five fragment ions per protein, and one 
peptide per protein. Protein identification parameters used in the database 
searching included a <10ppm mass accuracy tolerance, fixed modifications of 
carbamidomethylation of cysteine, and dynamic modifications of deamidation of 
asparagine, deamidation of glutamine, and oxidation of methionine.  
The algorithm utilised by the software during analysis usually relies on inclusion 
of the specific primary cleavage specificity of the enzyme used during the 
digestion process. For example, trypsin specificity is usually defined as 
cleavage C-terminal to arginine or lysine residues, except where a proline 
residue immediately follows. In reality, the situation is more complex, and the 
effect of trypsin on a peptide is also influenced by other surrounding peptides, 
particularly those which are negatively charged such as glutamate and 
aspartate (Figure 3.14). Such residues may result in a “missed cleavage” site in 
the peptide sequence, which can also be of use in analysing the data [Siepen et 
al 2007].  
In this study, the use of such specific searching resulted in extremely low 
numbers of protein identifications (less than 10 per sample). It was 
hypothesised that the non-specific breakdown of proteins as part of the process 
of post mortem decomposition before tissue fixation and processing was 
responsible for this. The software programme was therefore modified to allow 
assessment of all peptide cleavage sites, rather than a specific search for 
cleavages and missed cleavages related to the enzymes used in digestion. This 
approach markedly increased the protein identifications achieved, though at the 
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cost of a significantly increased analysis time, and some decrease in confidence 
in the protein identifications.  
 
Position relative to cleavage site 
P4 P3 P2 P1 P1' P2' P3' 
  
W Y or F R or K not R or K 
  
  
not R or K R or K W Y or F 
  
  
D or E R or K not R or K 
  
  
not R or K R or K D or E 
  
   
R or K not R or K D or E D or E 
D or E D or E not R or K R or K 
   
 
D or E not R or K R or K not R or K D or E 
 
  
not R or K R or K R or K 
  
  
not R or K R or K H 
  
   
R or K P   
  
Figure 3.14 Peptide sequence patterns imparting a negative effect on trypsin 
activity (as P4-P3-P2-P1-||-P1’-P2’-P3’-P4’ where cleavage takes place 
between P1 and P1’) After Siepen et al 2007 
 




Candidate biomarkers must be validated before translation into clinical use. The 
most efficient method for achieving this is by the development of multiple 
reaction monitoring based assays on a triple quadrupole tandem mass 
spectrometer. This allows targeted quantitation of proteins using specific 
peptides, with a number of major advantages over alternative methods including 
low cost, high specificity and high throughput. The technique involves the use of 
a triple quadrupole tandem mass spectrometer to filter and measure a target 
precursor mass (‘parent’) of the selected biomarker peptide (MS1), and 
collision-induced dissociation (CID) leading to the formation of specific mass 
product (‘fragment’) ions (MS2). The combination of a specific parent and 
fragment ion identification provides a characteristic ‘mass signature’ which, in 
combination with a unique retention time using reverse phase liquid 
chromatography, provides robust peptide identification. Relative quantitation is 
achieved by spiking samples with a known quantity of a non-human peptide 
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(e.g. yeast enolase Saccharomyces cerevisiae (ATCC 204508/S288c)). 
Absolute quantitation can be achieved by the use of an isotopically-labelled 
amino acid incorporated into a peptide with an identical sequence to the target 
peptide (“AQUA peptide”), used as an internal control.  
MRM method development was undertaken using a modification of previously 
used in the laboratory in which this work was undertaken using a Waters Xevo 
TQ-S mass spectrometer coupled to a Waters standard Acquity liquid 
chromatography system. 
 
3.3.2 Peptide selection 
 
Candidate peptides from proteins of interest may be selected using several 
techniques [James and Jorgensen 2010]. First, candidate peptides may be 
selected from previous biomarker discovery work. Second, the whole protein 
may be purchased and digested before itself being submitted for proteomic 
analysis, and peptides selected from the resulting data. Third, for proteins of 
interest which have not been identified in previous work, peptides can be 
selected based on openly published online data from other groups (e.g. using 
the Global Proteome Machine) and theoretical protein cleavage data (e.g. using 
Skyline). 
 
3.3.3 Preparation of peptides for tuning 
 
Selected peptides were custom synthesised by Genscript USA Inc. or Generon 
UK Ltd. The synthesised peptides that did not contain a cysteine residue were 
reconstituted in a solution of 50% acetonitrile.  Those containing a cysteine 
residue were carbamidomethylated using the following technique: Peptides 
were generally supplied as 1mg dry peptide. This was reconstituted in 1ml of 
50% acetonitrile to give a working concentration of 1mg/ml of peptide. The 
reconstituted peptide solution was divided between four Eppendorf tubes, each 
containing 0.25mg of peptide in 250µl, and dried using a speed vac. One of the 
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samples was reconstituted in 20µl of distilled water for carbamidomethylation, 
and the others were stored at -20° C for later use. 
The reconstituted peptide was reduced by addition of 3µl of 100mM Tris 
containing 0.195M 1,4-dithioerythritol, pH 7.8 and left shaking for 1 hour at room 
temperature. Carbamidomethylation was achieved by addition of 12µl of 100mM 
Tris containing 0.195M 2-iodoacetamide, pH 7.8, and left shaking for 45 
minutes at room temperature.  
A 1mg C18 spin column was equilibrated using 200µl of 50% acetonitrile 
containing 0.1% trifluoroacetic acid. This was centrifuged at 1,500 x g for one 
minute. The column was washed through with 200µl of 0.1% trifluoroacetic acid 
and centrifuged at 1,500 x g for one minute. The wash step was repeated a total 
of three times. The peptide sample was added to the column, centrifuged for 
thirty seconds at 1,500 x g, and the flow-through re-applied. The column was 
washed through with 200µl of 0.1% trifluoroacetic acid and centrifuged at 1,500 
x g for one minute. The wash step was repeated a total of three times. Elution of 
the bound peptide was achieved using a solution of 70% acetonitrile. The eluted 
peptides were dried down using a speed vac and reconstituted as required in a 
solution of 50% acetonitrile. 
 
3.3.4 Manual tuning of peptides 
 
An accurate mass of a precursor ion was determined using an MS1 scan with 
source settings of 2.5kV capillary voltage, 35 V cone voltage, and a desolvation 
temperature of 500°C. Gas flow settings were set to desolvation 1000L/hr, cone 
15 L/Hr, and nebuliser set at 7.0 bar. Low mass resolution was set to 2.8 and 
high mass resolution to 14.9 with a collision gas flow of 0.15 ml/min. 
A daughter scan was then performed on the precursor mass, and daughter ions 
with the best response were optimised with repeated scanning at differing 
collision and cone energies. Parent-daughter transitions were confirmed to be 
from the peptide of interest using commercially-available software (Skyline).  A 
retention time for the selected transitions was then determined by running the 
synthetic peptide through the liquid chromatography system using a method as 
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given in Figure 3.15 over a duration of ten minutes. Three transitions were 
selected for use for each protein of interest. 
 





1 I 0.8 97 3 0 
2 0.20 0.8 97 3 6 
3 7.00 0.8 60 40 6 
4 7.01 0.8 0.1 99.9 6 
5 8.00 0.8 0.1 99.9 6 
6 8.01 0.8 97 3 1 
7 10.00 0.8 97 3 1 
Figure 3.15 Liquid chromatography inlet method used for retention time 
determination for Multiple Reaction Monitoring 
 
3.3.5 Automated tuning of peptides  
 
As an alternative to manual tuning, reconstituted peptides can be ‘tuned’ using 
automatic methods programmed into the mass spectrometer software. In the 
case of the mass spectrometer being used (Waters Xevo TQ-S coupled to a 
Waters standard Acquity liquid chromatography system), an automated system 
“Intellistart” is pre-installed with the software and this was used for some 
peptide tuning. 
 
3.3.6 Experimental testing 
 
Once optimised, peptide detection in samples can be performed. Samples were 
prepared using the same methods as described above for biomarker discovery 
work on a Q-TOF mass spectrometer. The optimal quantity of digest to inject 
was established using repeated testing. It was not necessary to use molecular 
weight filters for the sample types used. Tests for different peptides and 
proteins were multiplexed together to avoid sample loss and increase 
throughput. Dynamic multiple reaction monitoring was performed over a ten 
minute gradient with a minimum of 0.01s dwell time for quantitative transitions 
and a minimum of twelve data points per peak.  
58 
 
A standard curve was prepared in water and sample matrix and run with each 
batch of samples to establish linearity and define the limit of detection. Inter- 
and intra-batch variation was determined by repeated sample injections over a 
number of days. A quality control sample created from pooled tissue was run at 
the start of each batch and repeated between every twenty samples. A variation 
in the quality control run of less than 15% was considered acceptable. 
 
3.3.7 Data analysis 
 
Data was analysed using Waters QuantLynx version 4.1 (Waters Corp. Milford; 
USA). Peak integration including smoothing and baseline subtraction was 
performed and the integrated peak areas ratioed to the internal standard. 
Absolute quantitation was performed by comparison with the known quantity of 
internal standard (yeast enolase Saccharomyces cerevisiae (ATCC 
204508/S288c)). 
 
3.4 Summary  
 
Given the necessity of using formalin-fixed paraffin embedded samples for this 
study, it has been necessary to refine the proteomic techniques being used in 
order to optimise the data obtained. A deparaffinisation method has been 
utilised and it has been shown that in such samples common protein assays are 
ineffective; necessitating alternative measures of protein content. Optimisation 
of the liquid chromatography inlet method has resulted in a significant increase 
in proteins identified from samples derived from formalin-fixed paraffin-
embedded tissue. In addition to allowing the use of formalin-fixed paraffin-
embedded tissue in this study, these advances in technique will be of use in 



















Infection is strongly implicated as aetiology for at least a proportion of 
unexplained sudden infant deaths. While some deaths may be due to a 
classical ‘sepsis’ mechanism, it has been hypothesised that bacteria may also 
result in infant deaths by means of toxin-mediated effects.  
A number of methods are available for identification of bacteria in clinical 
samples, several which may be applied to post mortem tissue. These include 
traditional culture with biochemical identification techniques, PCR analysis of 
16S rRNA [Kolbert and Persing 1999, Clarridge 2004], and analysis of bacteria 
by means of MALDI mass spectrometry [Holland et al 1996, Rodriguez- 
Sanchez et al 2016]. As discussed previously, it is difficult to assess the 
significance of bacteria in post mortem samples, and Chapters 5 and 6 of this 
thesis are dedicated to the identification of biomarkers which may assist in this 
regard.  
In contrast to the identification of bacteria in post mortem samples, with the 
exception of toxin testing for Clostridium difficile, there are currently no widely-
available tests for bacterial toxins which can be applied in clinical practice. The 
only feasible technique for most pathologists is referral of an isolate to a 
National Reference Laboratory for toxin genotyping. This is expensive and time 
consuming, and out of reach of ‘routine cases’ encountered in paediatric 
pathology practice. Furthermore, the presence of the gene for a toxin is not 
evidence of toxin production or a pathological effect induced by that toxin. In 
addition to genotyping, we are aware of at least one laboratory which utilises 
gel-based techniques for toxin identification, and there are reports in the 
literature of toxin testing using ELISA [Zorgani et al 1999, Shokrollahi et al 
2014], however these techniques are limited to research practice and are not 
widely available. 
A historic limitation to direct identification of toxin in clinical samples is the very 
low concentration of toxin which is present in biological fluids compared with the 
plethora of native proteins present. Proteomic techniques provide an 
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opportunity to develop a specific and sensitive test to directly identify protein-
based toxins in clinical samples, even when present at very low concentrations. 
There has been some limited application of proteomic techniques to bacterial 
toxin identification, including some which have utilised MRM-based methods 
[Andjelkovic et al 2016, Yang et al 2015, Silva et al 2015]. To date such 
approaches have been limited to small numbers of toxins and only a small 
number have been applied to human samples. Many relate to the presence of 
bacterial toxins in foodstuffs and there are no published examples of such 
techniques being applied in the context of infant death or post mortem testing. 
The aim of this work was, as proof of principle, to develop a direct test for 
bacterial protein toxins using targeted proteomics and multiple reaction 
monitoring mass spectrometry (MRM-MS) which could be successfully applied 
to post mortem samples. As they are relatively well characterised and have 
been implicated as a cause of sudden infant deaths, toxins produced by 
Staphylococcus aureus were selected for this project. Furthermore, in addition 
to the application of MRM-MS to toxin identification, it is also possible to use 
this technique to identify and separate bacteria by the identification of specific 
proteins [Larson et al 2013, Kruh-Garcia et al 2014]. It was therefore decided to 
develop MRM-MS methods for identification of Staphylococcus aureus and 
some of its common toxins with a view to combining the MRM methods into a 
single multiplex test, and applying them to bacterial isolates. 
 
4.2 Method development 
 
4.2.1 Bacterial identification 
 
Staphylococcus aureus were retrieved from beaded stored clinical isolates from 
six clinical cases at Great Ormond Street Hospital for Children between 2011 
and 2012. These included a variety of sites of infection, and variable expression 
of the gene for Panton Valentine Leukocidin. The basic anonymised 






Age Gender Sample Date 
sampled 





08/05/2011 S. aureus gene 
detected 
12B16783 3 years Male Pleural 
empyema 












Female Pus finger 
wound 




Female Pus right 
knee 
08/10/2012 S. aureus gene not 
detected 
Figure 4.1 Anonymised characteristics of six isolates of Staphylococcus aureus 
utilised for shotgun proteomic analysis 
 
To identify the most suitable and specific peptides for Staphylococcus aureus 
for development into an MRM-based targeted assay, a shotgun ‘omic’ analysis 
of Staphylococcus aureus was performed. The bacterial isolates were cultured 
on blood agar for 24 hours at 37ºC. For each sample, six colonies were 
removed from the agar plate using a wire loop and placed into an Eppendorf 
tube. The retrieved colonies were immersed in 50µl of 100mM Tris pH7.8 6M 
urea 2% ASB-14 to assist in the degradation of the bacterial cells. The samples 
were vortexed well, subjected to 10 freeze-thaw cycles in dry ice and then left to 
shake overnight. 
The samples were then reduced, digested with trypsin, prepared for LCMS, 
submitted to LCMS, and analysed according to the protocol described in 
Chapter 3. Bioinformatic analysis using ProteinLynx Global Server v.2.5 
(Waters Corp; Milford, Mass.) took account of the use of trypsin rather than 
utilising a non-specific approach. 
Analysis of the data revealed between 136 and 200 proteins identified in each 
of the six samples. In contrast to the usual application of comparative 
proteomics, where differential protein expression between samples is used to 
identify biomarkers, for this work it was necessary to identify proteins which 
were conserved between groups; these proteins being potential common 
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biomarkers for Staphylococcus aureus. Thirty-five proteins were identified which 
were present in all six strains (see Figure 4.2). Each of these proteins was 
assessed according to the criteria given in the flow chart in Figure 4.3. 
 
Protein name Gene Name 
Putative aldehyde dehydrogenase aldA 
Aspartyl glutamyl tRNA Asn Gln amidotransferase subunit B gatB 
50S ribosomal protein L11 rplK 
Thioredoxin trxA  
Cysteine synthase cysK 
Succinate dehydrogenase subunit B sdhB 
Cell division protein FtsZ ftsZ 
ALF1 Fructose bisphosphonate aldolase class 1 fda 
ALF2 Fructose bisphosphonate aldolase   fba 
Purine nucleoside phosphorylase DeoD type deoD 
Pyruvate dehydrogenase E1 component subunit alpha pdhA 
ODPB Pyruvate dehydrogenase E1 component subunit beta pdhB 
Ribose phosphate pyrophosphokinase prs 
Aconitate hydratase 1 acnA 
ATP synthase subunit alpha    atpA 
Succinyl CoA ligase ATP forming subunit alpha sucD 
Formate acetyltransferase   pflB 
Glutamine synthetase glnA 
Glyceraldehyde 3 phosphate dehydrogenase gap 
Dihydrolipoyl dehydrogenase pdhD 
Glycine cleavage system H protein gcvH 
Serine tRNA ligase serS 
FTHS Formate tetraydrofolate ligase fhs 
DNAK Chaperone protein DnaK   dnaK 
PCKA Phosphoenolpyruvate carboxykinase pckA 
EFG Elongation factor G fusA 
GREA Transcription elongation factor GreA greA 
NDK Nucleoside diphosphate kinase ndk 
EFTS Elongation factor Ts tsf 
ENO Enolase eno 
KPYK Pyruvate kinase pyk 
PGK Phosphoglycerate kinase pgk 
Transketolase tkt 
Trigger factor  tig 
Triosephosphate isomerase tpiA 
Figure 4.2 Common proteins identified in six strains of Staphylococcus aureus 





Figure 4.3 Flow chart detailing analysis of candidate peptides for 
Staphylococcal toxin identification 
 
There were five peptides from five proteins identified which satisfied the given 
criteria and should therefore, if identified in a sample, indicate with a high 
degree of confidence whether or not Staphylococcus aureus is present. The 
characteristics of these proteins are given in figure 4.4.  
The five peptides from these proteins were taken forward for development into 
an MRM method. They are all involved in essential metabolic processes such 
as glucose metabolism and protein synthesis; meaning they are more likely to 
be conserved than proteins which form part of mechanisms of evasion of the 
host immune response or antibiotic resistance. All the peptide sequences 
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chosen for use in targeted analyses were shown to be species-specific for 
Staphylococcus aureus and thus suitable marker peptides for this species of 
bacteria. 
Synthesised peptides were purchased (Generon Ltd; Maidenhead, UK) and 
used as the basis for development of multiple reaction monitoring tests, using 
both automated and manual tuning methods (as detailed in chapter methods). 
Following the development of the test, the three peptides with the strongest 
response were selected to form part of a multiplex test to accurately identify and 
quantify Staphylococcus aureus (See figure 4.5). This test was then used 




UNIprotID Gene Protein Function 
PFLB_STAAC Q5HJF4 pflB Formate 
acetyltransferase 
Regulates anaerobic glucose 
metabolism 
E5QTM2_STAAH E5QTM2 fusA Elongation factor 
G 
Catalyzes the GTP-dependent 
ribosomal translocation step 
during translation elongation 
D0K5P7_STAAD D0K5P7 tig Trigger factor Involved in protein export. Acts as 
a chaperone by maintaining the 
newly synthesized protein in an 
open conformation. 
EFTS_STAA9 A5ISE1 tsf Elongation factor 
Ts 
Associates with the EF-Tu.GDP 
complex and induces the 
exchange of GDP to GTP 
SYS_STAA9 A5INQ0 serS Serine—tRNA 
ligase 
Catalyzes the attachment of 
serine to tRNA(Ser) 
Figure 4.4 Characteristics of proteins from which peptides were selected for 
multiple reaction monitoring method development 
 
4.2.2 Toxin identification  
 
The toxins selected for development into the test are listed in figure 4.6, along 
with their associated pathological effects. This group of Staphylococcal toxins 
was selected having been described in the literature as causing severe illness 
in living patients, or being associated with Sudden Infant Deaths. Protein 
sequences from each toxin were retrieved from Uniprot (http://ww.uniprot.org/) 
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and theoretically digested using Skyline (AB Sciex LLC; Framingham, Mass.) to 






















544.7128 760.6167 56 16 
544.7128 873.7812 56 14 




581.5851 575.9317 56 8 
581.5851 680.1261 56 14 




729.2872 902.7066 6 22 
729.5400 547.1100 33 17 






432.4575 426.4793 8 6 
648.0319 639.0933 56 16 





703.4575 564.4673 2 30 
703.4575 694.5812 2 16 







662.6490 329.3157 52 18 
662.6490 769.6239 52 20 







539.5425 426.3608 60 20 
539.6063 634.6361 14 12 




578.0957 325.2861 14 30 
578.0957 528.5569 14 18 




516.6500 576.2200 38 9 
516.6500 739.2500 38 9 




583.7400 421.1700 40 25 
583.7400 649.2700 40 25 
875.7400 439.1900 55 30 
Enterotoxin I SEI 
618.0900 560.2400 43 11 
926.7300 995.3700 85 25 
618.2872 447.3298 6 18 
Figure 4.5 Final MRM Multiplex method including transitions for three S. aureus 




Suitable peptides were selected for each toxin and blast searched using Uniprot 
(http://ww.uniprot.org/) to ensure that there was no overlap with human or other 
proteomes which might compromise the utility of the test. Synthesised peptides 
were obtained (Generon Ltd; Maidenhead, UK) and an MRM method was 
developed for each using both manual and automated methods as described in 
Chapter 3. 
 
Toxin  Gene Mechanism of action Role in Disease/Infant Death 
Alpha-
haemolysin 
hly Binds to membrane of 
eukaryotic (host) cells 
resulting in release of low 
molecular weight molecules 
leading to eventual osmotic 
lysis 
Proven to play a role in 
damaging host organs/tissues 
e.g. in the formation of 
necrotising pneumonia due to 
S. aureus [Kebaier et al 2012, 




and soft tissue infections 






release of pro-inflammatory 
cytokines; usually produced at 
local site of infection rather 
than in blood 
Causes Staphylococcal toxic 
shock syndrome; present at 
increased levels in SIDS cases 
compared to controls [Zorgani 
et al 1999; Gordon et al 
1999]; S aureus strains 
producing this toxin have 
been identified in SIDS cases 







Cytolytic effect Causes purpura fulminans, 
skin sepsis (blistering skin 








Enterotoxin A entA Superantigen-mediated 
release of pro-inflammatory 
cytokines 
Present at increased levels in 
SIDS cases [Zorgani et al 1999, 
Highet and Goldwater 2009]; 
S aureus strains producing 
this toxin have been identified 




Toxin  Gene Mechanism of action Role in Disease/Infant Death 
Enterotoxin C1 entC1 Superantigen-mediated 
release of pro-inflammatory 
cytokines 
Causes Staphylococcal food 
poisoning and toxic shock 
syndrome. Present at 
increased levels in SIDS cases 
[Zorgani et al 1999, Highet 
and Goldwater 2009]; S 
aureus strains producing this 
toxin have been identified in 
SIDS cases [Weber et al 2011] 
Enterotoxin G entG Superantigen-mediated 
release of pro-inflammatory 
cytokines 
Causes Staphylococcal food 
poisoning syndrome; Present 
at increased levels in SIDS 
cases [Highet and Goldwater 
2009]; S aureus strains 
producing this toxin have 
been identified in SIDS cases 
[Weber et al 2011] 
Enterotoxin I SEI Superantigen-mediated 
release of pro-inflammatory 
cytokines 
Causes Staphylococcal food 
poisoning syndrome; S aureus 
strains producing this toxin 
have been identified in SIDS 
cases [Weber et al 2011] 
Abbreviations: SIDS: Sudden infant Death Syndrome 
Figure 4.6 Characteristics of Staphylococcal toxins chosen for method 
development 
 
4.3 Multiplex test and sensitivity/specificity testing 
 
As discussed above, the use of MRM allows the development of a rapid 
multiplex test which, using one sample, can both identify Staphylococcus 
aureus and its toxins. In order to achieve this, the transitions for Staphylococcus 
aureus identification and for each of the toxins were combined into a single 
MRM method. The details of this method are given in Figure 4.5. 
In order to establish the sensitivity and specificity of the test for Staphylococcus 
aureus, this multiplex method was applied to 40 clinical isolates which included 
samples of Staphylococcus aureus and other structurally similar species such 
as coagulase negative Staphylococci. A total of 45 isolates was originally 
selected in the laboratory, but detailed analysis of organisms present was not 
available for 5 samples (W, AG, AI, AJ, AR), and these samples were therefore 
not analysed. While sequencing for strain typing was not performed due to 
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funding constraints, the antibiograms of the selected isolates have been 
examined for clinical purposes and their variability indicates that a number of 
different strains of Staphylococcus aureus and coagulase negative 
Staphylococcus are present, as would be expected in routine clinical practice 
(see Figure 4.7). 
Positive control samples for toxins were derived from whole toxins for Alpha 
haemolysin (Sigma Aldrich Catalogue number H9395) and Enterotoxin A 
(Sigma Aldrich Catalogue number S9399). For other toxins, where whole toxin 
was not available, commercially available toxin-producing strains of 
Staphylococcus aureus were purchased from Public Health England (National 
Collection of Type Cultures; NCTC) (see figure 4.8) and incubated on the 
recommended media to produce colonies.  
The clinical isolates were prepared according to the technique used to prepare 
the original isolates (see above) and subjected to MRM-MS analysis using the 
multiplex method developed (illustrated in Figure 4.5). The results were blindly 
reported without knowledge of the bacterial identifications provided by the 
clinical microbiology laboratory using conventional methods. The results of the 
testing are given in Figure 4.9 and indicate a specificity of 94.7% and a 
sensitivity of 100% for identification of Staphylococcus aureus. A single sample 
was identified as positive by the multiplex assay, but was in reality positive for 
coagulase-negative Staphylococcus and Coliforms, but not Staphylococcus 
aureus. MRM-MS analysis of this sample was repeated and yielded the same 
result. There are two main possibilities which might explain this positive result; 
first, the sample may have been contaminated with Staphylococcus aureus and 
the sensitivity of this test is such that even small amounts would lead to positive 
identification, or second there may be interference from other proteins present 
in the sample, particularly given the presence of a number of organisms. While 
the sensitivity and specificity levels for the test are excellent, it should be noted 
that the numbers here are relatively small, and the sensitivity and specificity 
established by analysis of isolates may not be reproduced to the same level in 















A CNS A,T,V E,F,G,P  - n/a 
 CNS T,V A,E,F,G,P  - n/a 
B CNS A,T,V  E,F,G,P  - n/a 
C CNS A,G,T,V  E,F,P  - n/a 
D CNS A,T,V  E,F,G,P  - n/a 
E CNS A,T,V  E,F,G,P  - n/a 
F CNS A,G,T,V  E,F,P  - n/a 
G CNS A,G,T,V  E,F,P  - n/a 
H CNS A,G,T,V  E,F,P  - n/a 
I CNS A,G,T,V  E,F,P  - n/a 
J CNS A,E,G,T,V  F,P  - n/a 
K CNS A,G,T,V  E,F,P  - n/a 
L CNS A,T,V  F  - n/a 
M CNS A,T,V  F  - n/a 
 CNS T,V A,F  - n/a 
N SA A,G,V  E,P F MSSA 
O SA A,E,F,M,U  P  - MSSA 
P SA A,E,F,G,U  P  - MSSA 
Q CNS   - E,F,P  - n/a 
 Coliform A,AMC,AMP,C,CIP,G,PTZ  -  - n/a 
 Coliform A,AMC,C,CIP,G,PTZ  AMP  - n/a 
R SA A,E,F,M,U  P  - MSSA 
S SA A,E,F,M,U  P  - MSSA 
T SA U  F  - MRSA 
U SA E,F P  - MSSA 
V SA E,M F,P  - MRSA 
X CNS Not stated  -  - n/a 
Y SA A,E,F,G,U  P  - MSSA 
Z SA A,G,V  E,P F MSSA 
AA CNS  - F  - n/a 
AB SA A,E,F,G,U  P  - MSSA 
AC CNS Not stated   -  - n/a 
AD CNS A,E,L,RIF,TRIM  F,P,U  - n/a 
AE SA A,F,G  E,P,U  - MSSA 
AF SA  A,G,V  E,P F MSSA 
AH SA E,F P  - MSSA 
 Diptheroids Not stated  -  - n/a 
AK 
Mixed 
Coliforms Not stated 
 -  - n/a 
AL SA A,E,F,U  P  - MSSA 
AM SA A,E,F,G,U  P  - MSSA 
 P aeruginosa A,C,CIP,G   - PTZ n/a 
AN SA A,G,V  E,P F MSSA 












AP SA A,F,G,M,P,U  E  - MSSA 
 CNS Not stated  -  - n/a 
AQ SA A,E,F,G,U  P  - MSSA 
 
Enterococcus 
sp. Not stated 
 -  - n/a 
AS SA M,RIF,TRIM,U  E,F,P  - MRSA 
Abbreviations: A: Amikacin AMC: Amoxicillin/clavulanic acid AMP: Ampicillin C: Ceftazidime 
CIP: Ciprofloxacin E: Erythromycin F: Flucloxacillin G: Gentamycin L: Linezolid M: Mupirocin 
MSSA: Methicillin-sensitive Staphylococcus aureus MRSA: Methicillin-sensitive Staphylococcus 
aureus P: Penicillin PTZ: Piperacillin/tazobactam RIF: Rifampicin T: Teicoplanin TRIM: 
Trimethoprim U: Fucidin V: Vancomycin 
Figure 4.7 Antibiogram of clinical isolates used for sensitivity and specificity 
testing 
 
There were appropriate positive results in the positive control samples for 
Staphylococcal toxins. Of particular note is that while Staphylococcal 
enterotoxins are theoretically resistant to proteolytic enzymes such as trypsin, 
the positive results in these control samples indicate that the method developed 
allows trypsin-mediated cleavage. This is likely to be a consequence of 
disruption of the three dimensional structure of the protein by means of the 
incubation with urea and dithioerythritol, and the vast excess of trypsin which is 
used when compared with levels present in vivo.  
 
 
NCTC Number Feature of interest 
06571 Antibiotic sensitive strain; produces PVL* ɬ 
 
10655 Produces Enterotoxin C ɬ 
 
11962 Produces Enterotoxin A and Toxic Shock Syndrome Toxin 1 ɬ 
13300 Methicillin-resistant strain; produces Panton-Valentine 
Leukocidin ɬ 
 
* While this strain of S. aureus was originally reported to produce no toxins, there is some 
evidence that it may harbour the genes for the production of Panton-Valentine Leukocidin 
[Kearns, Ganner and Holmes 2006] 
ɬ Public Health England have no data regarding alpha-haemolysin production, but they state 
that the majority of strains are positive 
Figure 4.8 Strains of Staphylococcus aureus from the National Tissue Culture 




Sample Clinical ID Sample type Routine methods MRM Test 
A 13B72528 Blood peripheral art CNS x 2 NEGATIVE 
B 13B72252 Blood Hickman line CNS NEGATIVE 
C 13B72253 Blood PICC line CNS NEGATIVE 
D 13B72254 Blood portacath CNS NEGATIVE 
E 13B72254 Blood portacath CNS NEGATIVE 
F 13B72253 Blood PICC line CNS NEGATIVE 
G 13B72003 Blood peripheral vein CNS NEGATIVE 
H 13B72003 Blood peripheral vein CNS NEGATIVE 
I 13B72003 Blood peripheral vein CNS NEGATIVE 
J 13B71890 Blood Hickman line CNS NEGATIVE 
K 13B71890 Blood Hickman line CNS NEGATIVE 
L 13B70821 Blood peripheral vein CNS NEGATIVE 
M 13B70725 Blood Hickman line CNS x 2 NEGATIVE 
N 13B70827 Nasal swab SA POSITIVE 
O 13B70952 Leg skin swab SA POSITIVE 
P 13B71208 Neck abscess SA POSITIVE 
Q 13B70890 Atrial Berlin cannula CNS, Coliform x 2 POSITIVE 
R 13B70889 Leg wound swab SA POSITIVE 
S 13B70950 Foot skin swab SA POSITIVE 
T 13B70940 Swab [site not spec.] SA POSITIVE 
U 13B70506 Throat swab SA POSITIVE 
V 13B71188 Nasal swab SA POSITIVE 
X 13B71208 Neck abscess CNS NEGATIVE 
Y 13B71208 Neck abscess SA POSITIVE 
Z 13B70827 Nasal swab SA POSITIVE 
AA 13B69331 CSF CNS NEGATIVE 
AB 13B71209 Neck wound swab SA POSITIVE 
AC 13B71209 Neck wound swab CNS NEGATIVE 
AD 13B71245 Wound swab NOS CNS NEGATIVE 
AE 13B71219 Ankle skin swab SA POSITIVE 
AF 13B70827 Nasal swab SA  POSITIVE 
AH 13B71975 Sternal wound swab SA, Diptheroids POSITIVE 
AK 13B71094 Skin swab Mixed Coliforms NEGATIVE 
AL 13B71853 Gastrostomy site swab SA POSITIVE 
AM 13B71840 Right orbit SA, P aeruginosa POSITIVE 
AN 13B70827 Nasal swab SA POSITIVE 
AO 13B71854 Skin rash swab SA POSITIVE 
AP 13B71676 Ear swab SA, CNS POSITIVE 
AQ 13B71675 Foot skin swab SA, Enterococcus sp. POSITIVE 
AS 13B71794 Nasal swab SA POSITIVE 






The use of proteomics to identify bacterial specific peptides and multiple 
reaction monitoring to develop this process into a rapid test, has allowed the 
development of a test facilitating confident identification of Staphylococcus 
aureus and many of its major pathological exotoxins from clinical isolates. Blind 
testing on a number of Staphylococcal and other isolates showed a high 
specificity and sensitivity. 
While alternative methods have been used for the identification of bacteria and 
toxins, this test has a number of advantages. First, confident bacterial 
identification and testing for seven common pathological Staphylococcal toxins 
can be achieved with a single test, meaning that only small amounts of sample 
are required. Second, the multiplex method used for this test takes only 10 
minutes and costs only a few pounds. Third, this method may be easily 
translated to function on a standard tandem mass spectrometer found in most 
general hospital biochemistry departments; making toxin testing feasible in 
routine practice. When compared to the current alternatives, this represents a 
significant time and cost saving (for example, bacterial identification by MALDI 
mass spectrometry requires the purchase of a MALDI mass spectrometer, a 
regular charge for an updated database of organisms, and does not provide 
quantitative results). 
The method of developing the test may theoretically be applied to any organism 
or toxin allowing multiplex tests to be produced which cover a wide range of 
pathogenic organisms or toxins. While the test has been applied only to isolates 
taken from culture media, in theory this technique can be applied directly to 
biological fluids such as blood, CSF or tissue samples. In the context of this 
thesis, this has obvious potential for application to post mortem examinations, 
where it could form a part of a robust minimally invasive autopsy technique. 
Given appropriate samples, the test may be utilised to investigate further the 
role of toxins in SIDS. 
Perhaps most significantly, application of this and similarly designed tests to 
biological fluids allows the potential for utilising the test as a rapid tool in the 
assessment of living patients with apparent sepsis. With appropriate refinement 
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and automation, it is estimated that the test could be adapted to give a result in 
well under an hour with a minimal increase in cost. 
A further feature of interest is that with the inclusion of a known quantity of a 
standard peptide, such as yeast enolase or a stable isotopically-labelled peptide 
standard, MRM-based assays such as the Staphylococcal multiplex test allow 
absolute quantitation. The majority of the techniques currently available for 
bacterial and toxin identification are either binary tests (positive or negative), or 
semi-quantitative (present at a high, moderate or low level). With the 
development of appropriate reference ranges, absolute quantitation of bacteria 
and peptides may be of use in interpreting the significance of the presence of 
an organism in both the post mortem and live clinical contexts, and identifying 
likely contaminants. 
While initial sensitivity and specificity testing results are promising, these results 
are based on a relatively small number of isolates and translation to clinical 
practice will require validation using larger numbers of samples, including those 
from clinical tissues.  
 
4.5 Conclusion  
 
In conclusion, this piece of work has enabled the creation of a single, cheap, 
rapid, multiplex test for the identification of Staphylococcus aureus and seven of 
its pathological exotoxins, which can be adapted to run on most standard 
tandem mass spectrometers. Sensitivity and specificity is extremely high in 
isolates of cultured bacteria, and the technique can be easily applied to other 
bacteria and toxins. This test brings toxin testing within the reach of routine 
practice. A graphical representation (chromatogram) of the multiplex test is 
given in figure 4.10. 
In addition, the MRM method can be theoretically adapted to allow analysis of 
biological fluids; creating the possibility of rapid post mortem sampling on fluids 
taken during a minimally invasive autopsy examination. Perhaps more 
significantly, if successfully applied to biological fluids, it represents a rapid and 
cost-effective clinical test which could be used in the context of sepsis of 






Appropriate samples for developing this utility of the test could be obtained 
prospectively from intensive care units, which care for large numbers of patients 
with sepsis. Alternatively, archived samples could be used if available. 
The rapid and cost-effective nature of the test also means that prospective post 
mortem sampling from a large number of centres could be used as an 










As discussed in the introduction to this thesis, a major limitation to the 
investigation of infant deaths is the limited range of supplementary tests which 
are available to aid interpretation of post-mortem findings. In particular, while it 
is possible to identify bacterial organisms from samples taken during post-
mortem examinations, interpreting the significance of such findings is difficult. In 
life, the significance of an organism identified in a clinical sample can be 
assessed using a combination of the patient’s clinical history, current condition, 
examination findings, the results of white blood cell counts/differentials, and 
serum inflammatory marker levels. In a deceased patient undergoing post-
mortem examination, possibilities are necessarily much more limited. A 
particular limitation is the lack of reliable inflammatory markers. 
One of the aims of this piece of work is to use proteomics as a biomarker 
discovery tool to identify inflammatory markers which could be used in routine 
post-mortem practice. The first step in this process is to utilise comparative 
proteomics to compare the protein complement of tissues from individuals with 
and without infection. Differentially expressed proteins may then be further 




5.2.1 Case selection 
 
For the purposes of this work, cases were selected from the archive of post 
mortem tissue at Great Ormond Street Hospital for Children. In all cases, 
consent had been given by the parents for retention of tissue and use of tissue 
for research approved by the London (Bloomsbury) Research Ethics 
Committee. All cases selected were from post mortem examinations performed 
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prior to 2006, and therefore not subject to the requirements of the Human 
Tissue Act 2004. 
As part of a previous study at this centre, a database was created containing 
detailed anonymised data from each autopsy performed at the centre over a 
period of 14 years [Weber et al 2008a]. The fields collected include anonymised 
demographic information, clinical history, post mortem findings, and results of 
microbiological testing. The database has previously been used with some 
success to identify trends in infection in SUDI [Weber et al 2008b] and the 
database therefore formed a good basis for the identification of appropriate 
cases for inclusion in this study. 
Cases were selected for inclusion in one of four groups. A table containing 
details of each case in each group is given in figure 5.1. A description of the 
main features of each group and the rationale for their inclusion in the study is 
given below.  
 
5.2.2 Trauma (negative control group)  
 
Population-based studies of SUDI and SIDS usually rely on the inclusion of 
age-matched controls as the control group [Blair et al 2014]. It is never “normal” 
for a baby to die and as such a ‘control group’ in the context of post mortem 
investigations simply does not exist. It was therefore decided that for this study, 
where infection was the disease of interest, the most suitable negative control 
group would be infants who had died rapidly as a consequence of trauma. In no 
case selected was there a prolonged survival which might have given rise to 
infective/inflammatory complications such as ventilator-associated pneumonia 
or raised inflammatory markers secondary to head injury. None of the cases 
selected had any histological evidence of infection, and none had positive 










Negative Control Group (Trauma) 
 Head injury; NAI No Negative 
Head injury; NAI No Negative 
Rib fractures; NAI No Negative 
Head injury; NAI No Negative 
Head injury, multiple injuries; RTC No Negative 
Head injury; NAI No Negative 
Head injury; NAI No Negative 
Head injury; NAI No Negative 
Head injury; NAI No Negative 
   
Sepsis Group 
  Nil specific No Staphylococcus aureus in blood 
culture 
Nil specific No GBS in blood culture, spleen, lung 
Nil specific No GBS in blood culture, spleen, lung 
Nil specific No GBS in blood culture, spleen, lung 
Nil specific No GBS in blood culture, spleen, lung, 
trachea 
Nil specific No Staphylococcus aureus in blood 
culture, spleen 
Nil specific No Streptococcus pneumoniae in 
Blood, lung 
   
Positive Control Group (Meningitis) 
 Meningitis Yes Streptococcus pneumoniae in CSF 
Meningitis Yes Streptococcus pneumoniae in CSF 
Meningitis, HIE Yes Enterococcus in meningeal swab, 
lung 
Meningitis, mild LRTI Yes GBS in spleen, CSF, lung 
Meningitis Yes Streptococcus pneumoniae in CSF 
Meningitis Yes 
Staphylococcus epidermidis and 








Meningitis, pneumonia, empyema Yes Coliforms in CSF, urine, lung 
Meningitis, mild LRTI Yes Mixed growth all sites 
Meningitis, pericarditis Yes Mixed growth all sites 
Meningitis, miliary tuberculosis 
lungs, kidneys 
Yes 
Mycobacterium tuberculosis in CSF, 
lung 
   
Positive Control Group (Pneumonia) 
 
Pneumonia, tracheobronchitis Yes NG in lung, mixed growth other 
sites 
Pneumonia, HIE Yes Coliform in lung, mixed growth 
other sites 
Pneumonia, osteomyelitis Yes Staphylococcus aureus in blood 
culture, spleen, lung 
Pneumonia, empyema Yes Staphylococcus aureus in blood 
culture, spleen, lung 
Pneumonia Yes Staphylococcus aureus in blood 
culture, spleen, lung, HIV +, PJP 
lung Pneumonia Yes GBS in lung 
Pneumonia, HIE Yes Mixed growth all sites 
Pneumonia, bronchiolitis Yes Streptococcus pneumoniae in lung 
Pneumonia Yes 
Haemophilus influenzae type B and 
Streptococcus pneumoniae in lung, 
blood culture 
Pneumonia Yes Group A Streptococcus in lung, 
spleen, blood culture 
GBS: Group B Streptococcus, PJP: Pneumocystis jiroveci pneumonia 
Figure 5.1 Detailed summary of the characteristics of cases selected for 
proteomic analysis 
 
5.2.3 Infection – Meningitis (positive control group) 
 
The first positive control group consisted of individuals who had died of 
meningitis and in whom there was an appropriate clinical history, histological 
findings, and bacteriological evidence of infection. These cases included 
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infection with a number of different organisms including Neisseria meningitidis, 
Streptococcus pneumoniae, and Group B Streptococcus; the variety of causes 
was chosen in order to minimize the possibility that biomarkers discovered 
would be specific to the inflammatory process triggered by a particular 
organism. In some cases there was also evidence of infection at other sites, 
such as the lungs or kidneys. 
 
5.2.4 Infection – Pneumonia (positive control group) 
 
It was decided that a second positive control group was necessary in order to 
allow for possible differences in inflammatory marker production in different 
types of infection. This group consisted of individuals who had died of 
bronchopneumonia/lower respiratory tract infection. Like the meningitis group, 
all of the cases included had an appropriate clinical history, post mortem 
findings, and microbiological results. Again, the cases covered a variety of 
causative organisms in order to ensure any potential biomarkers were as widely 
applicable as possible. These organisms included Streptococcus pneumoniae, 
Group A Streptococcus, Pneumocystis jiroveci, Group B Streptococcus, 




As discussed in the introduction, deaths resulting from “Sepsis” prove 
particularly difficult at post mortem examination, as there may be no available 
clinical history or convincing histological findings. Histological evidence may 
also be missed as a consequence of inadequate sampling. For example subtle 
supporting evidence of sepsis such as reactive (secondary) haemophagocytic 
lymphohistiocytosis may be missed if lymph nodes, bone marrow or spleen are 
not examined histologically [Inai et al 2014]. Even where there is the suspicion 
of sepsis, interpretation of findings varies widely between consultants [Pryce et 
al 2011]. It was therefore decided to include a group of cases in which it was 
considered most pathologists would give the cause of death as sepsis, although 
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it is acknowledged that not all pathologists would agree with this interpretation 
in all cases. Cases included in this group have a positive culture result in blood 
and/or spleen and one other site, for an organism which, if it were discovered in 
the blood in life, would be considered pathological. In none of the cases was 
there histological evidence of infection, or a history or post mortem findings 
suggestive of an alternative cause of death. The cases predominantly involved 
Group B Streptococcus, but Staphylococcus aureus and Streptococcus 
pneumoniae were also represented in a small number of cases. 
With respect to numbers, even amongst a cohort of the size available (over 
1000 cases), it was difficult to find an appreciable number of cases which 
clearly satisfied the criteria for each group. Ten cases for the pneumonia and 
meningitis groups, seven cases for the sepsis group, and ten cases for the 
control group were therefore selected as a pragmatic compromise between 
achieving clean groups satisfying the inclusion criteria, and sufficient numbers 
for a representative selection. This was considered preferable to increasing 
case numbers by reducing the stringency of the selection criteria. Such 
numbers are generally acceptable in proteomic biomarker discovery studies of 
rare diseases. Given the small number of cases available, it was not possible to 
statistically balance the groups with respect to age, sex, or other potentially 
confounding factors. Nevertheless, a summary of these factors in each group is 
given in Figure 5.2. Statistical testing using an independent samples Kruskal-
Wallace test demonstrated no significant difference between the groups with 
respect to age (p=0.216) or post mortem interval (p=0.979). There are a 
generally higher number of males than females; which reflects the demographic 
of infant deaths.  
 
 




Post mortem interval 
median (range)/days 
Negative control (trauma) 
group 2 140 (10-299) 3 (1-7) 
Positive control (pneumonia) 
group 1.5 108.5 (57-290) 3 (1-6) 
Positive control (meningitis) 
group 1.5 144 (24-301) 3 (0-5) 
Positive control (sepsis) 
group 1.3 41 (31-176) 2 (1-4) 
Figure 5.2 Demographic details of experimental groups 
83 
 
Given that case selection was based on a database of cases, which was 
populated from post mortem reports, it was necessary to review the complete 
histology of all included cases in order to reliably exclude errors in the post 
mortem reports or database data entry. This review revealed evidence of 
significant pulmonary acute inflammation in one of the negative control cases 
which was not reported in the original post mortem report. This case was 
therefore excluded from the study and the negative control group therefore 
comprised nine cases. 
Samples of heart, liver, kidney, spleen and lung were selected as being 
representative of the major organs sampled routinely at post mortem 
examination. The use of spleen and lung for the biomarker aspect of the study 
was discontinued at an early stage as extracts from these tissues yielded far 
smaller peptide numbers than the other tissues (typically up to 10-fold lower). 
The reason for this is uncertain, however it is well recognized that haemoglobin 
can interfere with proteomic assessment due to its presence at high 
concentration in blood-stained samples. Given the high erythrocyte content of 
the splenic red pulp, it seems likely that this is the cause of the practical 
difficulties using this tissue. There are techniques which can filter out 
haemoglobin which are successfully used on samples in our laboratory, but 
these techniques add a degree of complexity to the sample preparation, which 
might limit the more widespread use of the tests developed. In the case of lung 
the low yields may be a consequence of the relatively low cellularity of this 
tissue type. 
 
5.2.6 Experimental process 
 
A sample of each tissue of interest (Heart, liver, and kidney) was removed from 
the formalin fixed paraffin embedded blocks from each of the cases selected. 
The samples were prepared for proteomic analysis by means of the 
experimental technique described in Chapter 3. Once prepared, the 
appropriately pooled, fractionated and digested, protein samples were analysed 
using liquid chromatography-Mass spectrometry (see Chapter 3). The data from 
each fraction were analysed using specialist proteomic software (ProteinLynx 
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Global Server) and combined to create a full set of results for each tissue type 
in each experimental group (meningitis liver, meningitis heart, pneumonia 
kidney etc.). The results in each of these groups were then compared and the 
results are given below. 
 
5.3 Results & Discussion 
 
The number of confident protein identifications achieved for each study group in 
each tissue type is shown in Figure 5.3. The number of identifications is lower 
than seen in some published studies, but is easily sufficient for biomarker 
discovery analysis. The lower number of identifications observed in this work 
compared to other studies is likely due to tissue being obtained from archived 
formalin-fixed samples, which are well recognised to achieve lower numbers of 
protein identifications than fresh tissue.  
 
 
Heart Liver Kidney 
Negative control group  44 (724) 115 (1368) 249 (4311) 
Positive control group (meningitis) 103 (1570) 151 (1658) 260 (4144) 
Positive control group (pneumonia) 204 (3731) 76 (800) 171 (2855) 
Positive control group (sepsis) 182 (2806) 80 (846) 262 (3902) 
Figure 5.3 Number of proteins identified per group (number of peptides) 
 
Using the data, proteins were selected as candidate biomarkers if they fell into 
one of two groups (increased in infection or decreased in infection), and the 
criteria for inclusion in these groups are given in Figure 5.4. A total of 41 
differentially expressed proteins were identified and these are listed in Figure 
5.5 along with a summary of their function. A protein interaction map generated 
using STRING [Szklarczyk et al 2015] is given in Figure 5.6. 
 
 
Trauma Meningitis Pneumonia Sepsis 
Increased in infection  -  +  +  +/- 
Decreased in infection  +  -  -  +/- 
Figure 5.4 Criteria for selection of proteins for further analysis (+ Detected, - not 








Gene Name Protein Name Protein function 
P01023 A2MG_HUMAN A2M Alpha-2-
macroglobulin 
Negative regulation of 
complement activation, 
lectin pathway 
P02649 APOE_HUMAN APOE Apolipoprotein E Negative regulation of 
inflammatory response 
Q9UHQ4 BAP29_HUMAN BCAP29 B-cell receptor-
associated protein 
29 
Regulation of membrane 
transport and apoptosis 
P01024 CO3_HUMAN C3 Complement C3 Central component of 
classical and alternative 
complement pathways 
Q8TD46 MO2R1_HUMAN CD200R1 Cell surface 
glycoprotein CD200 
receptor 1 
Negative regulation of 
inflammatory response 
(inhibits expression of 
pro-inflammatory 
molecules) 
P20273 CD22_HUMAN CD22 B-cell receptor 
CD22 
Mediates B-cell B-cell 
interaction 
P12111 CO6A3_HUMAN COL6A3 Collagen alpha-3(VI) 
chain 
Serine type protease 
inhibitor 




Involved in urea cycle 
(removal of excess 
ammonia from cell) 
O75390 CISY_HUMAN CS Citrate synthase, 
mitochondrial 
Involved in tricarboxylic 
acid cycle 
P01034 CYTC_HUMAN CST3 Cystatin-C Cysteine protease 
inhibitor (involved in 
cellular response to 
insults) 
Q93034 CUL5_HUMAN CUL5 Cullin-5 Cell cycle protein 
(involved in protein 
ubiquitination) 
Q7Z4W1 DCXR_HUMAN DCXR L-xylulose reductase Participant in glucose 
metabolism 
Q9NRZ9 HELLS_HUMAN HELLS Lymphoid-specific 
helicase 
Plays role in 
expansion/survival of 
lymphoid cells 
P02790 HEMO_HUMAN HPX Hemopexin Involved in heme 
transport to the liver; also 
implicated in 
immunoglobulin 
production and positive 
regulation of IFNγ 
mediated signalling 
P08238 HS90B_HUMAN HSP90AB1 Heat shock protein 
HSP 90-beta 










Gene Name Protein Name Protein function 
P34931 HS71L_HUMAN HSPA1L Heat shock 70 kDa 
protein 1-like 
Involved in regulation of 
cellular response to injury 
P11142 HSP7C_HUMAN HSPA8 Heat shock cognate 





P10809 CH60_HUMAN HSPD1 60 kDa heat shock 
protein, 
mitochondrial 
Involved in B-cell 




P13232 IL7_HUMAN IL7 Interleukin-7 Key factor in humoral 
immune response 
Q12906 ILF3_HUMAN ILF3 Interleukin 
enhancer-binding 
factor 3 
Involved in defence 
response to viruses; 
negative regulation of 
viral genome regulation 
Q9NWZ3 IRAK4_HUMAN IRAK4 Interleukin-1 
receptor-associated 
kinase 4 
Involved in Toll-like 
receptor and IL-1R 
signalling pathways as 
part of innate immune 
response 
Q8WWI1 LMO7_HUMAN LMO7 LIM domain only 
protein 7 
Involved in protein 
ubiquitination and cell 
signalling 
P26038 MOES_HUMAN MSN Moesin Involved in regulation of 
leukocyte migration and 
cell-cell adhesion 
Q13469 NFAC2_HUMAN NFATC2 Nuclear factor of 
activated T-cells, 
cytoplasmic 2 
Involved in B cell receptor 
signalling pathway; 
positive regulation of B 
cell proliferation 
Q9BYH8 IKBZ_HUMAN NFKBIZ NF-kappa-B 
inhibitor zeta 
Involved in regulation of 
inflammatory response via 
toll-like receptor and IL-1R 
signalling pathways 
P18669 PGAM1_HUMAN PGAM1 Phosphoglycerate 
mutase 1 
Key factor in 
gluconeogenesis 
P00558 PGK1_HUMAN PGK1 Phosphoglycerate 
kinase 1 
Key factor in 
gluconeogenesis 




Involved in cell response 
to injury, including that 
from lipopolysaccharide 
P41222 PTGDS_HUMAN PTGDS Prostaglandin-H2 D-
isomerase 
Involved in maintenance 
of blood-brain barrier; 









Gene Name Protein Name Protein function 
Q9H7Z7 PGES2_HUMAN PTGES2 Prostaglandin E 
synthase 2 
Involved in prostaglandin 
biosynthesis (part of lipid 
metabolism) 
P01009 A1AT_HUMAN SERPINA1 Alpha-1-antitrypsin Acute phase protein 
P01011 AACT_HUMAN SERPINA3 Alpha-1-
antichymotrypsin 
Acute phase protein 
P08697 A2AP_HUMAN SERPINF2 Alpha-2-antiplasmin Acute phase protein 
P05155 IC1_HUMAN SERPING1 Plasma protease C1 
inhibitor 
Involved in innate 
immune response and 
complement activation 




Cell division protein 
P00441 SODC_HUMAN SOD1 Superoxide 
dismutase [Cu-Zn] 
Destruction of free 
radicals formed by insults 
to cell 
P04179 SODM_HUMAN SOD2 Superoxide 
dismutase [Mn], 
mitochondrial 
Destruction of free 
radicals formed by insults 
to cell 
Q9Y2C9 TLR6_HUMAN TLR6 Toll-like receptor 6 Participates in innate 
immune response to 
Gram-positive bacteria 
and fungi 
Q12931 TRAP1_HUMAN TRAP1 Heat shock protein 
75 kDa, 
mitochondrial 
Involved in cellular 
response to stress 
P10599 THIO_HUMAN TXN Thioredoxin Involved in cellular 
response to stress 
P0CG48 UBC_HUMAN UBC Polyubiquitin-C Involved in innate 
immune response 
Figure 5.5 List of differentially-expressed proteins with summary of protein 
function 
 
It can be clearly established from the functions listed in Figure 5.5, that the 
differentially-expressed proteins identified cover a wide range of functions; 
many involving the immune response or the cellular response to stress (Figures 
5.7-5.9). It is of particular note that there appears to be no particular 
inflammatory pathway which is favoured over others, and proteins are 
represented that form part of the innate immune response, adaptive immune 
response, response to viruses, response to cell damage by chemicals/radiation, 
response to lipopolysaccharide, complement pathway, Toll-like receptor 
pathway, and acute phase protein cascade. These are promising candidates for 
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biomarkers which could be used in the detection of infection in the post mortem 
setting. Furthermore, these results may provide insight into the disease 
mechanisms and pathways involved in fatal sepsis in infants. 
There are also a small number of proteins which are not known to have a direct 
function in the immune or stress responses. These proteins are also suitable for 
further assessment, as they may prove to be useful markers even if not 
previously known to play a role in these processes. 
While the proteins identified in this biomarker discovery phase are promising, 
these proteins will need to be validated using other techniques and in larger 
cohorts of samples. In addition the data obtained was reliant on pooled 
samples, meaning that there is no way of distinguishing from this data the 
difference between a protein present at a raised level in all cases, and a protein 
present at a raised number in a small proportion of cases, or even in a single 
case. In order to establish which of these markers are reproducibly raised in a 
significant number of individual cases, targeted techniques must be used to 
identify each protein in individual samples. Tandem mass spectrometry using 
multiple reaction monitoring was selected for this purpose and this is described 
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Figure 5.7 Protein interaction map of differentially expressed proteins, with 
proteins involved in response to stress highlighted













Figure 5.8 Protein interaction map of differentially expressed proteins, with 
proteins involved in the innate immune response highlighted



















Figure 5.9 Protein interaction map of differentially expressed proteins, with 
proteins involved in the adaptive immune response highlighted









, generated using 
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Chapter 6 – The Development of a Targeted Proteomic Test for 




In the last chapter, a number of candidate biomarkers were identified using 
shotgun proteomic analysis. As stated previously, such candidates may or may 
not be suitable for use as biomarkers as a consequence of pooling of samples. 
In order to confirm which, if any, of the candidates can be used reliably as a 
biomarker for the disease of interest it is necessary to develop targeted tests for 
the proteins of interest and apply them to individual cases rather than pooled 
groups. This can be achieved using a number of different methods, including 
targeted mass spectrometry and immunohistochemistry. While 
immunohistochemistry might appear to be the most suitable technique in a 
study aiming to develop post mortem tests, there are a number of 
disadvantages which make targeted mass spectrometry a more attractive 
option. First, the development of each immunohistochemical test is extremely 
time-consuming. Second, high quality positive controls are required to optimise 
the method and these are not available. Third Immunohistochemistry does not 
allow quantitation. Finally, the sensitivity of immunohistochemistry is 
considerably lower than that of targeted mass spectrometry. In light of these 
considerations, targeted mass spectrometry using multiple reaction monitoring 
was selected as the confirmatory method of choice. This decision does not 
preclude the development of immunohistochemical stains for any identified 




Suitable peptides were selected or designed for each protein of interest 
identified in the biomarker discovery experiment (See Figure 5.5 in Chapter 5). 
These peptides were selected using a combination of methods as described in 
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Chapter 3. Where peptides were suboptimal, for example containing a cysteine 
residue, a second peptide was also selected for that protein. 
In addition to those proteins identified as potential biomarkers in the biomarker 
discover experiment, it was decided to include a number of proteins which are 
known to play key roles in the inflammatory process.  These proteins and their 
key functions (as described by UNIPROT; http://www.uniprot.org/) are given in 
Figure 6.1. Using freely-available functional annotation software (DAVID; 
https://david.ncifcrf.gov/) pathway diagrams with all the selected proteins 
highlighted have been generated and are given in Figures 6.2-6.4. These 
demonstrate the broad coverage of the innate and adaptive immune response 
which is covered by the selected proteins; maximising the chances of 









Protein Name Protein function [Uniprot] 




and complement fixation 




Ligand for the leukocyte 
adhesion protein LFA-1 
(integrin alpha-L/beta-2). 
Key role in leukocyte 
trans-endothelial 
migration 
P01579 IFNG_HUMAN IFNG Interferon gamma 
Produced by lymphocytes 
activated by specific 
antigens or mitogens. 
IFN-gamma, in addition to 
having antiviral activity, 
has important 
immunoregulatory 
functions. It is a potent 
activator of macrophages, 
and it can potentiate the 
antiviral effects of the 
type I interferons 
P22301 IL10_HUMAN IL10 Interleukin-10 
Inhibits the synthesis of a 
number of cytokines, 
including IFN-gamma, IL-
2, IL-3, TNF and GM-CSF 
produced by activated 











Protein Name Protein function [Uniprot] 
P01583 IL1A_HUMAN IL1A 
Interleukin-1 
alpha 
Produced by activated 
macrophages, stimulates 
thymocyte proliferation by 
inducing IL-2 release, B-
cell maturation and 
proliferation, and 
fibroblast growth factor 
activity. IL-1 proteins are 
involved in the 
inflammatory response, 
being identified as 
endogenous pyrogens. 
P01584 IL1B_HUMAN IL1B Interleukin-1 beta 
Potent proinflammatory 
cytokine. Initially 




influx and activation, T-
cell activation and 
cytokine production, B-
cell activation and 
antibody production, and 
fibroblast proliferation and 
collagen production. 
Promotes Th17 
differentiation of T-cells 
P60568 IL2_HUMAN IL2 Interleukin-2 
Produced by T-cells in 
response to antigenic or 
mitogenic stimulation, this 
protein is required for T-
cell proliferation and other 
activities crucial to 
regulation of the immune 
response. Can stimulate 
B-cells, monocytes, 
lymphokine-activated 
killer cells, natural killer 
cells 
P05231 IL6_HUMAN IL6 Interleukin-6 
Cytokine with a wide 
variety of biological 
functions. It is a potent 
inducer of the acute 
phase response. Plays an 
essential role in the final 
differentiation of B-cells 
into Ig-secreting cells 
Involved in lymphocyte 
and monocyte 
differentiation. Acts on B-
cells, T-cells. Required for 
the generation of T(H)17 
cells 
P0DJI8 SAA1_HUMAN SAA1 
Serum amyloid A-










Protein Name Protein function [Uniprot] 
P16581  LYAM2_HUMAN SELE E-selectin 
Cell-surface glycoprotein 
having a role in 
immunoadhesion. 
Mediates in the adhesion 





P01375 TNFA_HUMAN TNF 
Tumour necrosis 
factor alpha 
Cytokine that binds to 
TNFRSF1A/TNFR1 and 
TNFRSF1B/TNFBR. It is 
mainly secreted by 
macrophages. It is potent 
pyrogen causing fever by 
direct action or by 
stimulation of interleukin-
1 secretion 




Important in cell-cell 
recognition. Appears to 
function in leukocyte-
endothelial cell adhesion. 
Interacts with integrin 
alpha-4/beta-1 
(ITGA4/ITGB1) on 
leukocytes, and mediates 
both adhesion and signal 
transduction. The 
VCAM1/ITGA4/ITGB1 
interaction may play a 
pathophysiologic role both 
in immune responses and 
in leukocyte emigration to 
sites of inflammation 
Figure 6.1 Characteristics of additional inflammatory proteins selected for 




Figure 6.2 Pathway diagram of cytokines and the inflammatory response 
generated using DAVID Functional annotation software utilising pathway 
information generated by Biocarta [Huang, Sherman and Lempicki 2009]; 
proteins included for further analysis are highlighted. 
 
 
Figure 6.3 Pathway diagram of the cytokine network generated using DAVID 
Functional annotation software utilising pathway information generated by 
Biocarta [Huang, Sherman and Lempicki 2009]; proteins included for further 




Figure 6.4 Pathway diagram of the local inflammatory response to an insult 
generated using DAVID Functional annotation software utilising pathway 
information generated by Biocarta [Huang, Sherman and Lempicki 2009]; 
proteins included for further analysis are highlighted. 
 
The selected peptides were designed, synthesised commercially, prepared and 
tuned according to the technique given in Chapter 3. The selected proteins and 
the associated selected peptide are given in Figure 6.5. The individual methods 
were combined into five larger 10 minute multiplex methods in view of the 
limited amount of material available for analysis, and in order to increase the 
sensitivity and dwell time in the mass spectrometer (Figures 6.6-6.10). These 
tests were applied to the same groups of cases used for the biomarker 
discovery experiments, although the individual samples rather than pooled 
samples were used and the two infection groups were combined for analysis 
purposes. In addition to the groups used previously, a group of 19 unexplained 
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infant death cases were included in whom there were no significant clinical or 
post mortem findings, and in whom only commensal organisms or mixed 
bacterial growth were identified microbiologically. The general demographics of 
the groups are given in Figure 6.11. Analysis using an independent samples 
Kruskal-Wallis test showed no statistically significant difference between the 
groups with respect to post mortem interval (p=0.595) or age (p=0.058). There 
were generally more males than females; reflecting the demographics of infant 
deaths. 
Gene 
name Protein name Peptide(s) selected 
A2M Alpha-2-macroglobulin AFQPFFVELTMPYSVIR 
APOE Apolipoprotein E LGPLVEQGR 
BCAP29 B-cell receptor-associated protein 29 SSTSRPDAYEHTQMK 
C3 Complement C3 Established test used* 
CD200R1 Cell surface glycoprotein CD200 receptor 1 QITQNYSK 
CD22 B-cell receptor CD22 EVQFFWEK 
COL6A3 Collagen alpha-3(VI) chain QLGTVQQVISER 
CPS1 
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial FVHDNYVIR 




CS Citrate synthase, mitochondrial ALGVLAQLIWSR 
CST3 Cystatin-C ALDFAVGEYNK 
CUL5 Cullin-5 YVEQLLTLFNR 
DCXR L-xylulose reductase 
AVIQVSQIVAR 
TQADLDSLVR 
HELLS Lymphoid-specific helicase LISQIQPEVDR 
HPX Hemopexin YYCFQGNQFLR 
HSP90AB1 Heat shock protein HSP 90-beta SIYYITGESK 
HSPA1L Heat shock 70 kDa protein 1-like VEIIANDQGNR 
HSPA8 Heat shock cognate 71 kDa protein DAGTIAGLNVLR 
HSPD1 60 kDa heat shock protein, mitochondrial VTDALNATR 
ICAM1 Intercellular adhesion molecule 1 
LLGIETPLPK 
ASVSVTAEDEGTQR  






IL1A Interleukin-1 alpha  ESMVVVATNGK 
IL1B Interleukin-1 beta SLVMSGPYELK  








IL7 Interleukin-7 LNDLCFLK 
ILF3 Interleukin enhancer-binding factor 3 FVMEVEVDGQK 
IRAK4 Interleukin-1 receptor-associated kinase 4 SANILLDEAFTAK 
LMO7 LIM domain only protein 7 KPQDQLVIER 
MSN Moesin EDAVLEYLK 
NFATC2 Nuclear factor of activated T-cells, cytoplasmic 2 YQQQNPAAVLYQR 
NFKBIZ NF-kappa-B inhibitor zeta ASGQAVDDFK 
PGAM1 Phosphoglycerate mutase 1 AMEAVAAQGK 
PGK1 Phosphoglycerate kinase 1 VLPGVDALSNI 
PRDX3 
Thioredoxin-dependent peroxide reductase, 
mitochondrial GLFIIDPNGVIK 
PTGDS Prostaglandin-H2 D-isomerase 
TMLLQPAGSLGSYSYR 
AQGFTEDTIVFLPQTDK 
PTGES2 Prostaglandin E synthase 2 QWADDWLVHLISPNVYR 
SAA1 Serum amyloid A-1 protein  
EANYIGSDK 
SFFSFLGEAFDGAR  
SELE E-selectin YTHLVAIQNK 
SERPINA1 Alpha-1-antitrypsin LSSWVLLMK 




SERPING1 Plasma protease C1 inhibitor LVLLNAIYLSAK 
SMC4 Structural maintenance of chromosomes protein 4 SNNIINETTTR 
SOD1 Superoxide dismutase [Cu-Zn] Established test used* 
SOD2 Superoxide dismutase [Mn], mitochondrial LTAASVGVQGSGWGWLGFNK 
TLR6 Toll-like receptor 6 DMPSLEILDVSWNSLESGR 
TNF Tumour necrosis factor alpha 
ANALLANGVELR  
DNQLVVPSEGLYLIYSQVLFK 
TRAP1 Heat shock protein 75 kDa, mitochondrial ELGSSVALYSR 
TXN Thioredoxin LEATINELV 
UBC Polyubiquitin-C TITLEVEPSDTIENVK 
VCAM1 Vascular cell adhesion protein 1 
LHIDEMDSVPTVR  
NTVISVNPSTK  
*In two cases, multiple reaction monitoring methods for the protein of interest had already been 
developed in our laboratory by other researchers, these methods were therefore used to avoid cost and 
effort of duplication. 
Figure 6.5 Peptides selected for multiple reaction monitoring method 



























Post mortem interval 
(median 
(range))/days 
Negative control (trauma) group 2 140 (10-299) 2.5 (1-7) 
Positive control (infection) group 1.2 112 (24-301) 3 (0-6) 
Positive control (sepsis) group 1.3 41 (31-176) 2 (1-4) 
Unexplained SUDI group 1.7 62 (9-308) 2 (0-7) 
Figure 6.11 Summary of demographic details of the cases in each group of 




6.3.1 General findings 
 
Of the tests run on the different patient groups, 26 showed no measurable 
response in the individual samples, 15 showed a measurable response but with 
no significant difference between patient groups, and 12 showed a measurable 
response with a statistically significant difference between patient groups. A full 
breakdown of the proteins in each group is given in Figure 6.12. 
Those proteins showing statistically significant differences between groups can 
be divided into inflammatory markers which are increased in sepsis/infection, 
proinflammatory markers which are decreased in infection/sepsis, and 
mitochondrial/metabolic proteins which are increased in SIDS. Further 
discussion of each of these groups follows. 
 
6.3.2 Markers of infection/sepsis 
 
Three of the tested markers showed a statistically significant difference between 
the SIDS or control groups and the sepsis or infection groups; C-reactive 
protein, Heat shock cognate 71 kDa protein, and Heat shock 70 kDa protein 1-




Measurable response with 
significant difference between 
groups 
Measurable response with no 
significant difference between 
groups 
No measurable response 
C-reactive protein 
60 kDa heat shock protein, 
mitochondrial 















Heat shock protein 75 kDa, 
mitochondrial 
Prostaglandin E synthase 2 
Plasma protease C1 inhibitor 
Interleukin 10 
Alpha-1-antichymotrypsin 
Heat shock protein HSP 90-
beta 







Collagen alpha-3(VI) chain 
Serum amyloid A-1 protein 




Nuclear factor of activated T-





Cell surface glycoprotein 
CD200 receptor 1 
Toll-like receptor 6 









associated kinase 4 
Alpha-1-antitrypsin 
Phosphoglycerate mutase 1 





Structural maintenance of 
chromosomes protein 4 
NF-kappa-B inhibitor zeta 
Interleukin 7 
Interferon gamma 
Interleukin 1 beta 
Complement 3 
Superoxide dismutase [Cu-Zn] 










6.3.2a C-reactive protein (CRP) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of CRP between the control, sepsis, infection, and SIDS groups. 
Distributions of CRP detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. CRP levels were statistically significantly different 
between the different groups of cases, Chi2(3) = 15.286, p = 0.002. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in CRP levels between the 
Trauma (control) (21.61) and Infection groups (38.42) (p = 0.031), and the SIDS 
(22.05) and infection groups (p = 0.004), but not between any other group 




Figure 6.13 Graphical representation of C reactive protein measured in post 







6.3.2b Heat shock cognate 71 kDa protein (HSP7C) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of HSP7C between the control, sepsis, infection, and SIDS groups. 
Distributions of HSP7C detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. HSP7C levels were statistically significantly 
different between the different groups of cases, Chi2(3) = 11.848, p = 0.008. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in HSP7C levels between 
the SIDS (23.95) and Infection groups (36.65) (p = 0.031), but not between any 





Figure 6.14 Graphical representation of Heat shock cognate 71 kDa protein 







6.3.2c Heat shock 70 kDa protein 1-like (HS71L) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of HS71L between the control, sepsis, infection, and SIDS groups. 
Distributions of HS71L detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. HS71L levels were statistically significantly 
different between the different groups of cases, Chi2(3) = 26.790, p <0.001. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in HS71L levels between 
the SIDS (17.05) and Infection groups (36.65) (p = 0.002), the SIDS and sepsis 
groups (47.57) (p <0.001), and between the Trauma (control; 18.89) and sepsis 





Figure 6.15 Graphical representation of Heat shock 70 kDa protein 1-like 





6.3.3 Pro-inflammatory cytokines decreased in the infection/sepsis 
groups 
 
Unexpectedly, four pro-inflammatory cytokines which would be expected to be 
increased in the case of infection/sepsis were in fact decreased when compared 
with controls/SIDS cases; Interleukin 1a, Interleukin 6, Interleukin 2 and ICAM1. 
The detailed analysis of these proteins is described below: 
 
6.3.3a Interleukin 1a (IL1a) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of IL1a between the control, sepsis, infection, and SIDS groups. 
Distributions of IL1a detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. IL1a levels were statistically significantly different 
between the different groups of cases, Chi2(3) = 18.597, p <0.001. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in IL1A levels between the 
Infection (17.20) and Trauma (control) groups (39.89) (p = 0.002), and between 
the Infection and SIDS groups (35.45) (p = 0.002), but not between any other 
group combination (see figure 6.16). 
 
Figure 6.16 Graphical representation of Interleukin 1a measured in post mortem 
liver from four experimental groups 
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6.3.3b Interleukin 2 (IL2) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of IL2 between the control, sepsis, infection, and SIDS groups. 
Distributions of IL2 detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. IL2 levels were statistically significantly different 
between the different groups of cases, Chi2(3) = 28.438, p <0.001. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in IL2 levels between the 
Infection (17.45) and Trauma (control) groups (42.67) (p = 0.001), the Infection 
and SIDS groups (38.20) (p < 0.001), the Sepsis (14.56) and Trauma (control) 
groups (p = 0.002), and the Sepsis and SIDS groups (p = 0.003), but not 




Figure 6.17 Graphical representation of Interleukin 2 measured in post mortem 





6.3.3c Interleukin 6 (IL6) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of IL6 between the control, sepsis, infection, and SIDS groups. 
Distributions of IL6 detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. IL6 levels were statistically significantly different 
between the different groups of cases, Chi2(3) = 15.607, p = 0.001. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in IL6 levels between the 
Infection (21.13) and Trauma (control) groups (39.89) (p = 0.008), and between 
the Infection and Sepsis groups (39.44) (p = 0.016), but not between any other 




Figure 6.18 Graphical representation of Interleukin 6 measured in post mortem 







6.3.3d Intercellular adhesion molecule 1 (ICAM1) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of ICAM1 between the control, sepsis, infection, and SIDS groups. 
Distributions of ICAM1 detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. ICAM1 levels were statistically significantly 
different between the different groups of cases, Chi2(3) = 10.421, p = 0.015. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in ICAM1 levels between 
the Infection (18.84) and SIDS groups (34.65) (p = 0.015), but not between any 




Figure 6.19 Graphical representation of Intercellular adhesion molecule 1 







6.3.4 Markers increased in SIDS when compared with all other groups 
 
A group of five mitochondrial/metabolic proteins were statistically significantly 
increased in the SIDS group when compared with controls and the 
infection/sepsis groups: 60 kDa heat shock protein, mitochondrial, Carbamoyl-
phosphate synthase [ammonia], mitochondrial, Phosphoglycerate kinase 1, 
Polyubiquitin C, and L-xylulose reductase. The detailed analysis of these 
proteins is given below: 
 
6.3.4a 60 kDa heat shock protein, mitochondrial (CH60) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of CH60 between the control, sepsis, infection, and SIDS groups. 
Distributions of CH60 detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. CH60 levels were statistically significantly 
different between the different groups of cases, Chi2(3) = 10.483, p = 0.015. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in CH60 levels between the 
Trauma (control; 17.83) and SIDS groups (35.11) (p = 0.046), but not between 
any other group combination (see figure 6.20). 
 
 
Figure 6.20 Graphical representation of 60 kDa heat shock protein, 
mitochondrial measured in post mortem liver from four experimental groups  
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6.3.4b Carbamoyl-phosphate synthase [ammonia], mitochondrial (CPSM) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of CPSM between the control, sepsis, infection, and SIDS groups. 
Distributions of CPSM detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. CPSM levels were statistically significantly 
different between the different groups of cases, Chi2(3) = 10.277, p = 0.016. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in CPSM levels between 
the SIDS (37.42) and Infection groups (23.75) (p = 0.045), but not between any 




Figure 6.21 Graphical representation of Carbamoyl-phosphate synthase 








6.3.4c Phosphoglycerate kinase 1 (PGK1) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of PGK1 between the control, sepsis, infection, and SIDS groups. 
Distributions of PGK1 detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. PGK1 levels were statistically significantly 
different between the different groups of cases, Chi2(3) = 9.695, p = 0.021. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in PGK1 levels between the 
SIDS (33.74) and Sepsis groups (14.07) (p = 0.014), but not between any other 




Figure 6.22 Graphical representation of Phosphoglycerate kinase 1 measured 








6.3.4d Polyubiquitin C (UBC) 
 
Kruskal-Wallis test was conducted to determine if there were differences in 
detection of UBC between the control, sepsis, infection, and SIDS groups. 
Distributions of UBC detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. UBC levels were statistically significantly different 
between the different groups of cases, Chi2(3) = 13.482, p = 0.004. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in UBC levels between the 
Trauma (control; 17.44) and SIDS groups (37.58) (p = 0.010), and the Sepsis 
(18.57) and SIDS groups (p = 0.040), but not between any other group 




Figure 6.23 Graphical representation of Polyubiquitin C measured in post 







6.3.4e L-xylulose reductase (DCXR) 
 
A Kruskal-Wallis test was conducted to determine if there were differences in 
detection of DCXR between the control, sepsis, infection, and SIDS groups. 
Distributions of DCXR detected were not similar for all groups, as assessed by 
visual inspection of a boxplot. DCXR levels were statistically significantly 
different between the different groups of cases, Chi2(3) = 24.181, p <0.001. 
Subsequently, pairwise comparisons were performed using Dunn’s (1964) 
procedure with a Bonferroni correction for multiple comparisons. This post hoc 
analysis revealed statistically significant differences in DCXR levels between 
the Trauma (control; 10.11) and SIDS groups (40.53) (p <0.001), the Sepsis 
(21.57) and SIDS groups (p = 0.045), and the Infection (26.40) and SIDS 





Figure 6.24 Graphical representation of L-xylulose reductase measured in post 








6.4.1 A post mortem test for infection 
 
Statistically significant differences between groups were identified in 12/52 
(23%) of the tested markers, and three (3/52, 6%) were statistically increased in 
infection cases when compared with controls or SIDS cases and are therefore 
suitable biomarkers for use in identifying infection in SUDI cases. While it may 
appear disappointing that so many markers remained undetected in individual 
samples, in general terms it is expected that around 5% of markers identified in 
biomarker discovery experiments will be proved useful markers and the number 
identified in this study are clearly around this level. That so many markers 
remained completely undetected is likely to be a reflection of the very low 
relative concentrations at which inflammatory markers are present in vivo. 
The three markers identified with most potential for use as a test are C-reactive 
protein, and two heat shock proteins. C-reactive protein is member of the 
pentraxin family and acts as an acute phase protein which is generated in the 
liver in response to an inflammatory stimulus [Thompson, Pepys and Wood 
1999]. It acts by binding to lysophosphatadyl choline on the surfaces of some 
bacterial organisms and dying native cells, and activates the complement 
system via the classical pathway [Pepys and Hirschfield 2003]. It is in wide use 
in clinical practice as an inflammatory marker in hospital inpatients. It is not 
specific to infection and may be markedly raised in many inflammatory 
conditions and in response to trauma. Furthermore, small increases in CRP 
have been noted in a wide range of physical conditions even in the absence of 
infection or evidence of tissue injury [Antonelli and Kuschner 2017]. 
CRP measurement in post mortem samples has been investigated by a number 
of groups, primarily in serum and pericardial fluid [Palmiere and Augsberger 
2014], although one group also measured CRP in fresh liver samples after 
storage and found the levels to correlate well with serum levels [Astrup and 
Thomsen 2007]. A previous study in this group by Pryce and colleagues also 
examined CRP expression in liver in the same cohort of patients as used in this 
study be means of immunohistochemistry and found strong hepatocyte 
121 
 
expression in infection [Pryce et al 2014]. The current study is the first to 
quantitatively examine CRP levels in liver tissue which has been formalin-fixed 
and paraffin embedded; proving that the protein remains relatively stable for 
many years when processed and stored in this way.  
An interesting finding in the measurement of CRP in these cases is that the 
levels are significantly only in the infection group when compared with the 
control and SIDS groups. With regard to the control group this is an interesting 
finding because the majority of those cases involved trauma which is also 
known to result in a CRP rise in the living. It is likely that these deaths have 
occurred before that rise in CRP has occurred and this validates the used of this 
group of cases as a negative control group for infection. The significant 
difference when compared with the SIDS group suggests that a relatively small 
number of cases, or possibly no cases, of infection are being incorrectly 
included in the SIDS group (i.e. the number of missed cases of infection is likely 
to be low). 
The other two markers identified were Heat shock cognate 71 kDa protein and 
Heat shock 70 kDa protein 1-like. Both of these proteins are members of the 
heat shock protein 70 family and are encoded by the gene HSPA8 on 
chromosome 11, and HSPA1L on chromosome 6 respectively. They function as 
chaperone proteins and play important roles in protein folding and apoptosis 
[Mayer and Bukau 2005].  
Published research on Heat shock cognate 71 kDa protein focuses on its role in 
viral infection, particularly with respect to virally-induced malignancy [Takashima 
et al 2003, Moerdyk-Schauwecker, Hwang and Grdzelishvili 2009, Liu et al 
2013]. There are also studies which have identified a role for this protein in 
cases of bacterial infection; it was identified as a part of the pathway of 
lipopolysaccharide signal transduction [Triantafilou, Triantafilou, and Dedrick 
2001]. Detection of this protein in the clinical samples in this study showed a 
similar pattern of response as CRP, although the only statistically significant 
difference identified was between the infection and SIDS groups. 
Heat shock 70 kDa protein 1-like has been less extensively studied, but has 
been studied in the context of inflammation. Mutations in the gene HSPA1L 
have been reported to be increased in patients with inflammatory bowel disease 
when compared with controls [Takahashi et al 2017], and increased levels of 
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mRNA have been identified in patients with graft-versus-host disease [Atarod et 
al 2015]. It has also been suggested that the protein may play a role in the 
inflammatory response in trauma patients, but studies have been contradictory 
and whether this is a genuine association is unclear [Schroder et al 2003, 
Bowers et al 2006, Bronkhorst, Patka, and Van Lieshout 2015]. 
The pattern of expression in this study varied from that of the other two proteins, 
with extremely high levels seen in the sepsis cases when compared with the 
controls and SIDS cases, and increased levels in infection cases when 
compared with SIDS cases. The extremely high levels in the sepsis cases 
(around 30 times the levels seen in controls and 10 times the levels in infection 
cases) are particularly interesting as they imply that those cases which 
pathologists conclude are likely to be the consequence of “sepsis” are different 
from both the cases of histologically-proven infection and the cases categorised 
as SIDS. This is reassuring in that it implies that pathologists may be right to 
highlight sepsis as a possible cause of death in these cases, although given the 
relatively small number of sepsis cases in this study, further work would be 
required to conclude this with certainty.  
With respect to the aims of this thesis (i.e. the creation of a multiplex test to 
accurately identify infection in post mortem cases), these three markers have 
significant potential. The positive and negative rates for each marker in the 
control and Infection groups are given in Figure 6.25. Included in this figure are 
also figures for positive and negative rates in the control and infection groups if 
the three markers were to be used as a multiplex, with positive results for any 
two being considered a positive result. 
 
C-reactive 
protein HSP7C HS71L 
Any two of the three 
markers positive 
Infection 12/20 (60%) 14/20 (70%) 17/20 (85%) 18/20 (90%) 
Controls 1/9 (11%) 2/9 (22%) 3/9 (33%) 1/9 (11%) 
Figure 6.25 Positive and negative rates for potential markers of infection in the 
infection group and control group 
 
Using this data, specificity, sensitivity and other relevant parameters were 
calculated for a combined test of the three markers, with detection of any two of 
the three being considered a positive result. The results of this analysis are 
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given in Figure 6.26. These findings clearly indicate that the test using these 
parameters is appropriate for use in the post mortem setting, where for a 
Coroner’s purposes a sensitivity and specificity of only 51% would be required 




Positive Predictive Value 94.7% 
Negative Predictive Value 80.0% 
False Positive rate 11.1% 
False Negative Rate 10.0% 
Figure 6.26 Sensitivity, specificity and other parameters of a test for infection in 
liver from infant deaths undergoing autopsy using three markers (CRP, HSP7C 
and HS71L), with positivity in any two of the three markers being interpreted as 
a positive result 
 
It should be noted that the combined test using the positive parameters 
discussed above would identify only two of the sepsis cases (sensitivity 28.6%, 
specificity 88.9%). It is notable that while the sepsis cases clearly behave 
differently than the controls and SIDS cases, they also behave differently than 
the infection cases; raising the possibility of an alternative inflammatory 
pathway. As an alternative to the test defined above, given the extremely high 
level of HS71L in the sepsis cases, if a level of HS71L more than 30 fold the 
level in the control group was considered a positive test result, all but one of the 
sepsis cases would have been correctly identified (sensitivity 85.7%, specificity 
88.9%). Using this definition of a positive test only one of the infection group 
would have been labelled as sepsis, and since levels of the other two markers 
were also raised in this case it would also have been labelled as infection. 
This study has therefore shown the potential utility of a multiplex test comprising 
tests for CRP, HSP7C and HS71L (Figure 6.27), with a positive result for any 
two of the three markers having a high sensitivity for tissue infection, and if the 
test was negative using these parameters, a positive result for HS71L at a level 
greater than 30 times the baseline level in the control group, has a high 
sensitivity for sepsis without evidence of tissue infection. Given the relatively 
small numbers used in this method development, the test would benefit from 
further sensitivity and specificity testing in a larger group of unselected cases 






6.4.2 Decreased detection of pro-inflammatory cytokines in infection 
cases 
 
Statistically significant differences between the infection and sepsis groups and 
the SIDS and control groups were observed in four pro-inflammatory cytokines: 
Interleukin 1a, Interleukin 2, Interleukin 6, and Intercellular adhesion molecule 1. 
What is interesting about these results is that they are essentially in the 
opposite direction than one would expect (i.e. the levels of these markers are 
lower in infection than in controls). The pattern of response in the CRP and heat 
shock proteins described above, which is exactly what would be expected in 
infection, suggests that this is not error related to the tests performed or the 
sampling undertaken. 
There is an increasing recognition that ‘inflammation’ is in fact a complex 
interaction of pro and anti-inflammatory pathways and that immunological 
dysfunction is an important factor in the response to sepsis [Bermejo-Martin et 
al 2016]. Studies have shown alteration in the function of both monocytes and 
dendritic cells in severe sepsis, with decreased production of pro-inflammatory 
cytokines [Poehlmann et al 2009, Bhardwaj et al 2015, Fan et al 2015, Shalova 
et al 2015]. One possibility is that such acquired immunological dysfunction is a 
significant factor in infants who die suddenly and unexpectedly as a 
consequence of infection. This seems a more likely explanation than the 
obvious alternative, which is that all of these children have some form of 
immunodeficiency which is yet to be described. 
Although they represent the largest group of explained deaths in infants, fatal 
infection in the context of SUDI is a relatively under-investigated area from a 
pathological perspective as the cause of death is usually readily apparent. In 
light of these striking results, further investigation of these patients is warranted 
with a view to determining if there is any element of immune paresis which 
might be predicted, and therefore targeted so as to avoid a proportion of these 
deaths. This would be an interesting area of collaboration with intensive care 





6.4.3 Upregulation of metabolic pathways in SIDS 
 
The final group of statistically significant differences involved five proteins which 
form part of the normal metabolic machinery of the cell, in particular the 
mitochondria. These proteins were statistically significantly increased in SIDS, 
but not in the other groups of cases. These proteins are: 60 kDa heat shock 
protein, mitochondrial, Carbamoyl-phosphate synthase [ammonia], 
mitochondrial, Phosphoglycerate kinase 1, Polyubiquitin C, and L-xylulose 
reductase.  
While all of these proteins are involved in the normal metabolic functioning of 
the cell, three of the proteins have been suggested to have some role in 
inflammatory pathways. Carbamoyl-phosphate synthase [ammonia], 
mitochondrial is postulated to play a role in lipopolysaccharide binding, and 60 
kDa heat shock protein, mitochondrial, and Polyubiquitin-C are thought to have 
roles in the innate and adaptive immune response [Uniprot; 
http://www.uniprot.org/]. 
While there is a possibility that the upregulation of these proteins in SIDS 
represents evidence that there is an underlying inflammatory component to 
SIDS deaths, it is also possible that this represents a non-specific increased 
metabolic response to another stimulus, such a prolonged agonal period 
caused by deaths due to respiratory causes. It is not possible to determine the 




Targeted testing of a group of inflammatory markers discovered through 
biomarker discovery techniques and selection based on data from the literature 
has identified a total of 15 proteins whose concentrations in post mortem 
formalin-fixed paraffin-embedded liver differ significantly between disease 
groups. It has been shown that three proteins used in combination can be used 
to identify infection and sepsis in these cases with a high degree of sensitivity 
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and specificity. This can be rapidly translated into a test for routine clinical use, 
for example in minimally-invasive post mortems. 
Statistically significant decreases in common pro-inflammatory cytokines were 
identified in the infection group when compared with other groups and this 
supports the role for immune dysregulation as a significant aspect of the 
physiological response to infection in infants dying suddenly and unexpectedly. 
Finally, a statistically significant increase in a group of metabolic proteins in 
SIDS when compared with the other disease groups raises the possibility of a 
prolonged agonal period or other cause for increased metabolic demand in 
these cases. These two findings require further investigation in order to 




















The principle aim of this thesis was to utilise proteomic techniques to further 
investigate infection as a potential cause of SIDS. A particular aim of the work 
was to detect new biomarkers and develop them into a robust test for infection 
in post mortem tissue which could be used to identify cases of infection which 
may be being missed and incorrectly being defined as SIDS cases. This has the 
dual benefit of giving accurate information to the family of the deceased infant, 
and any healthcare professionals involved in their care before their death, and 
of removing infective deaths from the SIDS umbrella; allowing more accurate 
research studies. The techniques applied during the work have allowed the 
identification of markers for infection, sepsis, specific bacteria, and bacterial 
toxins, and have provided valuable insight into the mechanisms which may 
underlie both infant deaths due to infection, and infant deaths arising as a 
consequence of other causes. These outcomes are discussed further below in 
the context of current understanding of this area of investigation. 
 
7.2 Markers of infection and sepsis in autopsies 
 
As was discussed in the introduction to this thesis, not only is infection the most 
common cause of explained SUDI, but there are numerous factors which imply 
that infection or inflammation may play a significant role in the pathogenesis of 
SIDS. While it is not difficult to identify bacteria in the post mortem period using 
conventional microbiological techniques such as culture, interpreting the 
significance of any bacteria identified is difficult and interpretation in clinical 
cases varies widely between pathologists [Pryce et al 2011]. A major hindrance 
to the interpretation of these findings is the lack of robust, widely-available 
inflammatory markers which may indicate that any identified bacteria was 
having a physiological effect in the infant. While a number of inflammatory 
markers have been recommended for use in post mortem samples [Palmiere 
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and Augsburger 2014, Palmiere and Egger 2014], there are significant 
limitations to these techniques which limit their use in practice.  
First, analysis of such markers often relies on specialist tests or equipment 
which may not be available at a local laboratory and may be extremely costly. 
Second, studies of candidate markers have generally been performed on fluids 
such as pleural fluid, CSF, or serum, which may be difficult to collect in 
sufficient quantity to allow the routine testing which forms part of infant death 
investigation and the novel investigations recommended. Finally, the reliability 
of such markers for identification of infection, rather than inflammation from 
other sources, is not proven in large scale cohorts of patients. 
Using proteomic techniques to identify candidate biomarkers and then develop 
targeted tests to these biomarkers and to others identified in the literature, it has 
been possible to identify a group of three proteins which, when used in 
combination allow the identification of infection and sepsis in post mortem 
formalin-fixed paraffin-embedded liver samples with a high degree of sensitivity 
and specificity. This test uses multiple reaction monitoring on a tandem mass 
spectrometer; a technique which may be easily translated for use on the mass 
spectrometers available in local centres with minimal cost in terms of money 
and time. 
The real benefit of these markers over previously published tests is the genuine 
potential for use in clinical practice which they present, in addition to the use of 
a widely available tissue which, as this study has proved, remains suitable for 
analysis for many years after the post mortem examination has taken place. 
This allows both prospective and retrospective use of the test. 
With the advent of the Medical Examiners system, which was initially planned 
as part of the Coroners and Justice Act 2009, and in the context of an 
increasingly multicultural population, there is great demand from the public and 
Coroners for tests which might allow full invasive post mortem examinations to 
be avoided in favour of more limited examinations. Much of the research in this 
area has so far focussed on the application of radiological techniques to the 
deceased in an effort to establish the cause of death [Addison, Arthurs, and 
Thayyil 2014]. The development of this test allows the rapid diagnosis of 
infection or sepsis on the basis of a post mortem liver biopsy; a technique which 
is likely to be much more acceptable to the public than a full invasive autopsy, 
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and provides diagnosis of infection with a sensitivity and specificity far above 
that required by the Coroner. There is also good evidence that minimally 
invasive post mortem examinations are more acceptable to families [Lewis et al 
2017] 
The finding that sepsis may be distinguished from infection is useful clinically, 
but is also reassuring in that it the diagnosis of sepsis in post mortem cases at 
present is based on rather non-evidence based interpretation of the species of 
bacteria present and their location in the body. The fact that the sepsis cases 
show a response to the inflammatory marker panel which differs from that of 
controls indicates that there is something different about these cases from an 
inflammatory perspective which would be consistent with sepsis. However, it 
must be noted that the pattern of marker response also differs from that 
identified in infection; suggesting that the ‘sepsis’ deaths may be arising as a 
consequence of a different inflammatory mechanism. 
 
7.3 Infection and sepsis as causes of SIDS 
 
In addition to the development of a reliable test for infection and sepsis, the 
application of the developed tests to a variety of infection cases, sepsis cases, 
SIDS cases, and controls, has allowed a greater insight into infection both as a 
cause of SUDI and of SIDS. While many authors hypothesise that at least a 
proportion of SIDS cases arise as a consequence of undiagnosed infection 
[Goldwater 2017], the fact that so few of the SIDS cases in this study tend to 
cluster with the infection or sepsis cases when the tests are applied suggests 
that a very small number are due to undiagnosed infection or sepsis. This does 
not necessarily mean that other SIDS cases aren’t the consequence of a 
disturbance in the inflammatory network; rather it may indicate that these 
deaths are not occurring by the same mechanism as ‘classical’ infection or 
sepsis deaths. 
Over the last decade there has been a shift in the infant death literature to a 
focus on a more complex inflammatory theory of SIDS causation involving the 
integration of key bacterial species, toxin production, genetic predisposition, and 
other risk factors (particularly smoking) [Moscovis et al 2004, Goldwater 2017]. 
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The data arising from this study goes some way to supporting the supposition 
that SIDS deaths do not arise as a consequence of a more straightforward 
‘classical’ infective mechanism. 
Another interesting finding in this study was the increased concentration of a 
number of metabolic proteins in the SIDS cases when compared with the other 
disease groups. This also provides some support to the suggested inflammatory 
cause of some SIDS cases discussed above, in that a number of these proteins 
are known to play a role in inflammatory pathways but, as the data from this 
study shows, they are not significantly upregulated in infection or sepsis. 
Neither are they involved in the same inflammatory pathway; although to some 
extent the network of interactions in inflammation is sufficiently complex that all 
pathways of inflammation interact at some stage. This supports the theory of an 
alternative and more complex inflammatory mechanism than classical sepsis. 
However, this does not fully explain the findings of this study, as two of the 
metabolic markers increased in the SIDS group are not known to play any direct 
role in infection. This raises the possibility that the increase of these five 
proteins in SIDS cases is in fact more representative of a generally increased 
metabolic demand in SIDS than in other cases. Clearly infection causes an 
increased metabolic demand, but the SIDS cases have a much higher increase 
in the proteins than the infection group.  
Increased metabolic demand may be seen in a number of physiological and 
disease states, including a prolonged agonal period. There are a number of 
SIDS theories which relate to mechanisms which would give rise to a prolonged 
agonal period, particularly theories which involve central respiratory depression 
[Machaalani and Waters 2014, Salomonis 2014, Bergman 2015]. It is possible 
that the increase in these metabolic proteins identified in the SIDS cases is a 








7.4 Immune dysregulation in SUDI arising from infection 
 
Another key finding of this study is the decreased concentration of four key pro-
inflammatory cytokines in the proven cases of infection. Other studies have 
shown an increase in such markers in cases of infection [Pereira et al 2014], but 
the area has not been extensively researched from a pathological perspective 
as the cause of death is usually clear.  
There is a growing recognition that the physiological response to infection is far 
more complex than had previously been suspected, with the inflammatory 
response representing a complex interplay of pro- and anti-inflammatory 
pathways [Bermejo-Martin et al 2016]. It is well established that some pro-
inflammatory pathways are downregulated in cases of severe sepsis; 
particularly those relating to monocyte and dendritic cell activation and antigen 
presentation [Poehlmann et al 2009, Bhardwaj et al 2015, Fan et al 2015, 
Shalova et al 2015]. The observed low levels of the pro-inflammatory cytokines 
in the infection cases in this study raises the possibility that such immune 
dysregulation is a key mechanism in infants dying suddenly and unexpectedly 
of infection. This may go some way to explaining why some infants appear to 
die of infective causes rapidly and with minimal symptoms in the community, 
where most infants have sufficient time from onset of symptoms to collapse to 
allow presentation to medical care, treatment and recovery. As this is a 
relatively newly developing area, it has not been extensively investigated, 
particularly in the context of infant deaths, although other abnormalities of the 
monocyte activation pathways have been shown in neonates and infants 
[Heinemann et al 2016, Juskewitch et al 2015]. Further investigation of these 
mechanisms in the context of explained infant deaths has the potential to enrich 
the understanding of infection as a cause of death, and perhaps more 







7.5 Bacterial and toxin identification and quantitation using tandem 
mass spectrometry 
 
One of the established theories in the study of SIDS is the possibility of deaths 
arising as a consequence of toxin production by bacteria [Morris et al 1987]. 
Like the inflammatory processes in infection discussed above, the recent 
literature has seen a move to theories which integrate bacterial toxin production 
with other factors such as nicotine exposure, genetic polymorphism, and the 
inflammatory response [Moscovis et al 2004, Goldwater 2017]. 
A limitation in the investigation of theories of infant death relating to toxins is the 
lack of suitable and widely applicable tests for common bacterial toxins. Specific 
qualitative and quantitative methods of identification are available, but not 
outside funded research studies. Even in clinical practice focussed on living 
patients, direct toxin measurement is rarely used and reliance is placed on 
genotyping of suspected toxin-producing strains from cultured organisms.  
The use of the proteomic techniques in this study has allowed, as proof of 
principle, the development of a direct assay allowing quantitation of 
Staphylococcus aureus and its major toxins. This test may be translated to run 
on most mass spectrometers available in local hospital biochemistry 
departments, and is relatively cheap. It is therefore of considerable potential in 
the further investigation of toxin-based theories of SIDS by the routine 
application of direct toxin identification in prospective post mortem cases. It also 
has potential for use as a rapid test for toxins in living children to allow 




In conclusion, this study has allowed a greater insight into the mechanisms of 
infection in explained infant deaths, and the potential inflammatory and 
metabolic mechanisms underlying unexplained infant deaths. A rapid, low cost, 
easily translatable assay has been developed which can detect and distinguish 
infection and sepsis in post mortem material; allowing use in the context of 
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routine practice and, in the future, limited autopsies. As proof of principle, a test 
has also been developed to allow the identification and quantitation of specific 
bacteria and bacterial toxins, which has the potential to greatly aid the 
knowledge and understanding of the role of toxins in SIDS. 
The combined output of this work is substantial and has the potential for 










There are a number of limitations to this work which were the consequence of 
the necessary use of post mortem and archived tissue. The principle limitations 
lay in the availability of material for research use. The source material was 
drawn from cases undertaken at Great Ormond Street Hospital, London over a 
period of many years; a centre which undertakes a relatively large number of 
paediatric post mortem examinations. Nevertheless it was only possible to 
identify a small number of suitable cases for inclusion in the positive and 
negative control groups for the study.  
Furthermore, as was discussed at length in the method and results chapters, 
even though numerous methods are now described for the extraction of 
samples from formalin-fixed paraffin-embedded tissue, such extracts continue 
to perform poorly in proteomic studies when compared with fresh tissue, and 
the presence of post mortem autolysis requires significant adjustments to the 
analysis of the data obtained. As described in the method development chapter, 
protein assay is also compromised in formalin-fixed paraffin-embedded tissue; 
making comparison of samples challenging. 
While this study has demonstrated that useful results can be achieved in such 
circumstances, the combined effect of the relatively small case number and 
suboptimal sample type is that further biomarker discovery/mechanism 
identification work in this area will continue be difficult; taking more time and 
money than similar studies on fresh tissue, with an increased possibility of poor 
quality data limiting results and interpretation.  
Nevertheless, there are numerous avenues of interest in SIDS which could be 
very effectively explored by means of comparative proteomics and associated 
techniques such as transcriptomics, metabolomics, and lipidomics. If new 
guidelines were introduced that include the routine storage of fresh tissue in 
SUDI cases (with consent), this would open up immense potential for the use of 
these techniques in investigating SIDS. This is an established research tool 
used in numerous areas including tumour biology and degenerative brain 
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disease, and systems used for collection of samples in these areas could be 
utilised as a template for the creation of a SUDI tissue bank. 
An added complication in the context of SUDI are the limitations imposed by the 
Human Tissue Act, and the perceived negative public perception of paediatric 
post mortem research following the organ retention scandals of the last century. 
Nevertheless there is clearly a fundamental difference between systematic 
sampling of small fresh tissue samples for research in an open, transparent 
way, and retention of whole organs with no parental knowledge or consent. 
Properly managed, and with the support of parental groups, such a tissue bank 
could be effectively advocated to parents, the Chief Medical Officers, the Chief 
Coroner, and the Human Tissue Authority. Even were specific consent required 
in every case, there are few enough SIDS cases in each year that one 
dedicated research nurse at the centre where the bank is held could contact 
every family suffering an unexpected infant death to discuss and obtain consent 
for sampling for research. 
It is conceivable that there may be some resistance from pathologists to such 
an approach, particularly given that it will involve close collaboration between 
centres and some investment of time. However, the investigation of infant 
deaths needs to move forward from basic morphological assessment of the 
deceased to an integrated examination involving next generation tests and 
active participation in research. It may be that it is desirable in the long term to 
centralise the investigation of such cases to a small number of specialist 
centres who are able to provide an integrated examination which includes 
molecular and genetic testing and a research contribution. This would also have 
the advantage of increasing the experience and expertise of the pathologists 
performing the examinations. The potential disadvantages of centralisation, 








8.2  Future work 
 
A number of exciting potential areas for future research have arisen from the 
research forming the basis of this thesis, which have the potential to contribute 
greatly not only to the investigation of infant deaths, but also to the investigation 
of disease in the living. 
 
8.2.1 Application of tests to routine infant death investigation 
 
A small number of further research steps are required before the tests 
developed during this research can be routinely applied in post mortem 
practice. First, the refined inflammatory marker test must be applied to a large 
cohort of unselected historic cases in order to establish its specificity, sensitivity 
and robustness as a diagnostic test. There is also a role for prospectively 
applying the test in routine practice in a pilot centre or small number of centres. 
This will have the effect of proving the utility of the test in practice.  
Once the utility of the test is proven, it can easily be applied in clinical practice, 
either by sending of samples to a reference laboratory for testing, or by applying 
the test locally. A great advantage of the MRM-based tandem mass 
spectrometry method is that it can be straightforwardly translated onto any 
tandem mass spectrometer, such as may be found in most district general 
hospital laboratories. 
The test also has great utility for incorporation into less invasive autopsies by 
means of applying the test to biopsy samples taken following imaging studies. 
 
8.2.2 Further investigation of the mechanisms of infant death 
 
The development of a robust test for Staphylococcus aureus and many of its 
major toxins is a valuable tool which may now be applied to samples from post 
mortem examinations in infant deaths resulting from infection and SIDS cases. 
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This has the potential to add greatly to the understanding of the disease 
mechanisms which may play a role in the aetiology of SIDS and sepsis. 
Using the techniques applied in this study, it is also possible to investigate other 
areas of mechanistic interest in SIDS, and indeed some groups have already 
used proteomics to approach the issue of central nervous system development 
in SIDS [Broadbelt et al 2012, Hunt et al 2016].  
The increased integration of proteomics with other ‘omic’ techniques such as 
genomics, transcriptomics, metabolomics, and lipidomics also opens the door to 
using ‘omic’ technology to investigate abnormalities in SIDS identified using 
these other techniques. For example, inactivating protein mutations identified in 
whole exome studies in SIDS cases, which has been recommended as routine 
practice [Morris 2015], could be further investigated by proteomic analysis of the 
downstream pathways which such proteins regulate. 
The identification of increases in a number of metabolic proteins also has 
potential for further investigation with regard to whether it represents part of a 
more complex inflammatory aetiology, or a less specific agonal response to 
other stimuli, for example central respiratory depression. These markers may be 
applied to larger number of cases of infants dying in more varied circumstances, 
including as a consequence of asphyxia and metabolic disease, to further 
characterise the meaning of these observed changes. 
 
8.2.3 Investigation of disease in the living 
 
While a number of inflammatory markers are in common use in clinical practice, 
such as C-reactive protein (CRP), there are still areas in which novel tests for 
established markers would be of use. A good example of this is in the context of 
intensive care medicine in head injury, where CRP is known to rise over the 
days following injury, giving rise to a clinical difficulty when there is suspected 
concurrent infection (such as ventilator-associated pneumonia). The application 
of this new panel of inflammatory markers to samples from intensive care 
patients presents an opportunity for development of a small panel of markers 
allowing a distinction to be drawn between infection and other processes. 
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As discussed at length in the bacterial and toxin identification chapter, while 
there are numerous methods available for bacterial identification in clinical and 
post mortem samples, options for identification and quantification of toxins are 
extremely limited. For practical purposes, toxin expression testing in clinical 
isolates is limited to genotyping at a reference laboratory. The Staphylococcus 
aureus/Staphylococcal toxin test can be applied to clinical isolates and allows 
positive identification of Staphylococcus aureus and a quantitative assessment 
of its toxins. This test requires significant further testing using large numbers of 
clinical isolates to ensure its efficacy before it can be reliably used clinically, but 
samples are so freely available that this should be achievable in a relatively 
short space of time at minimal cost. If it proves to be reliable in large numbers of 
cases, then a very useful application for the technology is in rapid positive 
identification of bacteria in sepsis in the Accident and Emergency Department 
setting. Adapting the laboratory technique to allow rapid processing would take 
a small amount of work and a relatively slight increase in cost.  
Using the technique applied in this study, there is also potential for developing 
similar tests for other bacterial toxins of interest which can be tested for 
individually, or using a multiplex method. Furthermore, there is no reason why 
this technique could not be expanded to include other pathogens to rapidly 
identify the pathogen causing an infection; allowing early therapy with 
appropriate specific antibiotics. Such a precision medicine-based approach 
might prove invaluable in approaching the problem of broad spectrum antibiotic 
use and antibiotic resistance. 
 
The identification of cytokine downregulation suggestive of immune 
dysregulation in infants dying suddenly and unexpectedly of infection raises the 
possibility of a more complex inflammatory mechanisms underlying fatal 
infection in this patient group. Application of these markers to a wider variety of 
fatal infection samples, and to samples of infants suffering infection severe 
enough to require intensive care therapy may provide valuable insights into the 
pathophysiology of infection and allow the development of preventative or 




8.2.4 Investigation of other inflammatory conditions 
 
Another very useful outcome of the research is the development of a large 
panel of inflammatory markers. Although only a proportion of these have proven 
useful in identifying infection in SUDI, the larger panel of markers is still of use 
in other areas of research where inflammatory markers may be of interest, 
including inflammatory bowel disease and autoimmune disease. Furthermore, 
there is increasing recognition that inflammatory pathways may play a role in 
complex chronic disorders, particularly in neurodegenerative diseases [Hong, 
Kim and Im 2016]. Quantitative interrogation of these markers may now be 
incorporated into studies of a wide range of conditions using the methods 




In summary, while there were unavoidable limitations surrounding the samples 
available for examination, this research has resulted in a number of outcomes 
which will be useful in clinical practice. First, it has allowed the development of a 
multiplex inflammatory marker test which has shown to be effective in the 
identification and distinction of infection and sepsis in post mortem formalin-
fixed paraffin-embedded tissue. Second, it has allowed the development of a 
multiplex test allowing identification and quantitation of Staphylococcus aureus 
and its principle toxins. Both of these tests will be of great use in the 
development and refinement of the post mortem examination in Sudden 
Unexpected Deaths in Infancy, and in understanding the mechanisms 
underlying these deaths. Furthermore, they may also be of use in assessment 
of living patients in the Emergency Department and Intensive Care settings. The 
methods for individual inflammatory markers developed during the biomarker 
discovery phase of this research can be applied to clinical samples from a wide 
range of clinical conditions in which inflammatory markers may be of interest, 
such as inflammatory bowel disease, autoimmunity, and neurodegenerative 
conditions. Finally, the insights into the physiological mechanisms underlying 
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fatal infection in infants may be further investigated so as to advance 
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